Leping

PRISM Consortium Agreement, version 1.1., 11th July, 2025 Consortium Agreement JA PRISM Joint Action Prevention oriented RIghts-based approach to Support Mental health in vulnerable population groups Version 1.1 – 11th July, 2025 Based on DESCA – Model Consortium Agreement for Horizon Europe Version DESCA HE 2.0 – February 2024 © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024  PRISM Consortium Agreement, version 1.1, 11th July 2025 Table of Contents Consortium Agreement ......................................................................................................................... 4 1 Definitions ...................................................................................................................................... 8 2 Purpose ........................................................................................................................................ 12 3 Entry into force, duration and termination ............................................................................... 12 4 Responsibilities of Parties.......................................................................................................... 13 5 Liability towards each other ....................................................................................................... 17 6 Governance structure ................................................................................................................. 19 7 Financial provisions .................................................................................................................... 27 8 Results .......................................................................................................................................... 30 9 Access Rights .............................................................................................................................. 33 10 Non-disclosure of information ................................................................................................... 37 11 Miscellaneous .............................................................................................................................. 38 12 Signatures .................................................................................................................................... 41 Attachment 1: Background included ................................................................................................. 72 Attachment 2: Accession document ............................................................................................... 102 Attachment 3: List of Third Parties for simplified transfer according to Section 8.3.2. ............ 103 Attachment 4: Identified entities under the same control according to Section 9.5 .................. 105 Attachment 5: NDA for Advisory Board agreed under Section 6 ................................................. 106 © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 2 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Change Records Version Date Changes Version 1.0 5th May 2025 Initial version of the JA PRISM Consortium Agreement Version 1.1 11th July 2025 Version including feedback from partners REMARKS This Consortium Agreement model is for JA PRISM and will be a complement to the Grant Agreement of the Action entitled Joint Action Prevention oriented RIghts-based approach to Support Mental health in vulnerable population groups. The Horizon Europe DESCA (Development of a Simplified Consortium Agreement) model was used to draft the document and it was adapted to address the features of PRISM as DESCA models are created for projects which will be governed by a Horizon Europe Model Grant Agreement (MGA), i.e. notably “Research and Innovation Actions” and “Innovation Actions”. For the sake of clarity and, to comply with article 9 of the Grant Agreement, which states that the Beneficiaries must ensure that their relevant contractual obligations also apply to the Associated Partners, the latter shall also sign this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 3 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Consortium Agreement THIS CONSORTIUM AGREEMENT, hereinafter referred to as “Consortium Agreement”, is based upon Regulation (EU) No 2021/695 of the European Parliament and of the Council of 24 March 2021 establishing a Programme for the Union’s action in the field of health (‘EUHealth Programme’) for the period 2021-2027, and repealing Regulation (EU) 282/2014, and on the European Commission’s General Model Grant Agreement and it Annexes, and executed as of the 1st day of September, 2025 (the “Effective Date”). BETWEEN: ASOCIACIÓN INSTITUTO DE INVESTIGACIÓN EN SISTEMAS DE SALUD-BIOSISTEMAK (BIOSISTEMAK), PIC 955006420, established in B ACCELERATOR TOWER (BAT), GRAN VIA, 1, 48001 BILBAO, Spain, the Coordinator; AGENCIA DE SALUT PUBLICA DE BARCELONA (ASPB), PIC 983180264, established in Plaça Lesseps 1, 08023 BARCELONA, Spain, CONSEJERIA DE SANIDAD DE LA COMUNIDAD DE MADRID (DGSP CSCM), PIC 876845566, established in CALLE ADUANA 29, MADRID 28013, Spain, FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (IDIBAPS), PIC 999477525, established in CARRER ROSSELLO 149, BARCELONA 08036, Spain, FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA (IDIVAL), PIC 946556944, established in AVENIDA CARDENAL HERRERA ORIA S N, SANTANDER 39011, Spain, FUNDACION PUBLICA MIGUEL SERVET (FMS), PIC 966802493, established in CALLE IRUNLARREA 3 CENTRO INVESTIGACION BIOMEDICA RECINTO COMPLEJO HOSPITALARIO DE NAVARRA, PAMPLONA 31008, Spain, SERVICIO ANDALUZ DE LA SALUD (SAS), PIC 998853621, established in AVENIDA DE LA CONSTITUCION 18, SEVILLA 41071, Spain, GESUNDHEIT ÖSTERREICH GMBH (GÖG), PIC 928836208, established in STUBENRING 6, WIEN 1010, Austria, SCIENSANO (Sciensano), PIC 906160809, established in JULIETTE WYTSMANSTRAAT 14, ELSENE 1050, Belgium, HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH), PIC 998128255, established in ROCKEFELLEROVA 7, ZAGREB 10000, Croatia, ORGANISMOS KRATIKON YPIRESION YGEIAS (SHSO), PIC 891074787, established in Agiou Antoniou 2, Aglantzia NICOSIA 2100, Cyprus, NARODNI USTAV DUSEVNIHO ZDRAVI (NIMH), PIC 999462684, established in TOPOLOVA 748, KLECANY 250 67, Czechia, REGION SJAELLAND (RZDK), PIC 998373665, established in ALLEEN 15, SOROE 4180, Denmark, SOTSIAALMINISTEERIUM (MSAE), PIC 998429731, established in Suur-Ameerika 1, TALLINN 10122, Estonia, © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 4 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 TERVEYDEN JA HYVINVOINNIN LAITOS (THL), PIC 996697893, established in MANNERHEIMINTIE 166, HELSINKI 00271, Finland, MINISTERE DU TRAVAIL, DE LA SANTE, DE LA SOLIDARITE ET DES FAMILLES (MoH FR), PIC 998887377, established in AVENUE DUQUESNE 14, PARIS CEDEX 75350, France, BUNDESINSTITUT FÜR ÖFFENTLICHE GESUNDHEIT (BIÖG), PIC 998190723, established in MAARWEG 149-161, KOELN 50825, Germany, ETHNIKOS ORGANISMOS DIMOSIAS YGEIAS (EODY), PIC 896563726, established in 3-5 AGRAFON ST., ATHENS 15123, Greece, ORSZAGOS KORHAZI FOIGAZGATOSAG (OKFO), PIC 891516331, established in DIOS AROK 3, BUDAPEST 1125, Hungary, ISTITUTO SUPERIORE DI SANITA (ISS), PIC 999978821, established in Viale Regina Elena 299, ROMA 00161, Italy, BERNU KLINISKA UNIVERSITATES SLIMNICA VALSTS SIA (BKUS), PIC 904374748, established in VIENIBAS GATVE 45, RIGA 1004, Latvia, LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (SAM), PIC 933839468, established in VILNIAUS G 33, VILNIUS LT 01506, Lithuania, VILNIAUS UNIVERSITETAS (VU), PIC 999893170, established in UNIVERSITETO G. 3, VILNIUS 01513, Lithuania, LIETUVOS SVEIKATOS MOKSLU UNIVERSITETAS (LSMU), PIC 972782446, established in A MICKEVICIAUS GATVE 9, KAUNAS 44307, Lithuania, MINISTARSTVO ZDRAVLJA (MoH MNE), PIC 921159143, established in RIMSKI TRG 46, PODGORICA 81000, Montenegro, MINISTERIO DA SAUDE (MS), PIC 986364095, established in Av. João Crisóstomo, 9, LISBOA 1049- 062, Portugal, NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ), PIC 948891346, established in TRUBARJEVA CESTA 2, LJUBLJANA 1000, Slovenia, PUBLIC HEALTH INSTITUTE OF THE REPUBLIC OF SRPSKA (PHI RS), PIC 897817160, established in Jovana Dučića 1, Banja Luka, 78000 Republic of Srpska, Bosnia and Herzegovina, THE FEDERAL MINISTRY OF HEALTH (FMoH), PIC 916051608, established in Titova 9, Sarajevo, 71000, Bosnia and Herzegovina, JAVNA ZDRAVSTVENA USTANOVA DOM ZDRAVLJA BANJA LUKA (DZ BL), PIC 898971654, established in Sime Matavulja bb, Banja Luka, 78000 Republic of Srpska, Bosnia and Herzegovina, hereinafter, jointly or individually, referred to as “Beneficiaries” or “Beneficiary” SERVICIO MADRILEÑO DE SALUD (SERMAS), PIC 999481987, established in Paseo De la Castellana 280, 28046 Madrid, Spain, hereinafter, jointly or individually, referred to as “Associated Partners” or “Associated Partner” © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 5 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 hereinafter Beneficiaries and Associated Partner(s), jointly or individually, referred to as “Parties” or ”Party” relating to the Action entitled Joint Action Prevention oriented RIghts-based approach to Support Mental health in vulnerable population groups in short JA PRISM hereinafter referred to as “Project” © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 6 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 WHEREAS: The Parties, having considerable experience in the field concerned, have submitted a proposal for the Project to the Granting Authority as part of the EU4Health Programme, and the Parties entered into the Grant Agreement preparation phase with the Granting Authority. At the end of the Grant Agreement preparation phase, the Coordinator will be requested to sign the ensuing Grant Agreement No. 101233316 (hereinafter “Grant Agreement”) on behalf of the other Beneficiaries, which afterwards will access to this Grant Agreement by signing an accession form. Several Parties, being Associated Partners and not Beneficiaries, will not sign the Grant Agreement. Therefore, for the proper implementation of the Project, the Parties, including their Affiliated Entities, wish to specify or supplement binding commitments among themselves in addition to the provisions of the specific Grant Agreement to be signed by the Beneficiaries of the Project and the Granting Authority (hereinafter “Grant Agreement”). The Parties acknowledge that they are responsible for the compliance of their Affiliated Entities with the relevant EU provisions (Grant Agreement and its annexes) and this Consortium Agreement. The Parties are aware that this Consortium Agreement is based upon the DESCA model consortium agreement (Version DESCA HE 2.0, February 2024), that is adapted to address the features of JA PRISM. NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS: © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 7 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 1 Definitions 1.1 Definitions Words beginning with a capital letter shall have the meaning defined either herein or in the EU4Health Regulation or in the Grant Agreement including its Annexes. 1.2 Additional Definitions “Affiliated Entity” or “Affiliated Entities” (AE) entities affiliated to a beneficiary within the meaning of Article 190 of EU Financial Regulation 2024/25099 which participate in the action with similar rights and obligations as the Beneficiaries (obligation to implement action tasks and right to charge costs and claim contributions). entities affiliated to the nominated Competent Authorities: these are organizations that have a distinct legal personality but are linked to the nominated Competent Authority. “Associated Partners” (AP) entities that participate in the Joint Action without receiving funding and without claiming contributions. They do not become party to the Grant Agreement (do not sign it), but they implement important parts of the action and are thus involved actively in the consortium. “Background” means any data, know-how or information — whatever its form or nature (tangible or intangible), including any rights such as intellectual property rights — that is: held by the Parties (or that a Party has a right to license) before they acceded to this Consortium Agreement and (a) developed or acquired by a Consortium Member independently from the work in the Joint Action even if in parallel with the performance of the Joint Action, but solely to the extent that such data, information, know-how and/or IPRs are used in or introduced into the Joint Action by the Party who owns or has the right to license it, (b) Needed to implement the Project or Exploit the Results. (c) (d)is listed in Attachment 1 of the Consortium Agreement. If background is subject to rights of a Third Party, the Party concerned must ensure that it is able to comply with its obligations under the Agreement. “Beneficiary or Beneficiaries” (BEN) means a Beneficiary or the Beneficiaries to this Consortium Agreement also identified as the Beneficiaries to the Grant Agreement. The signatories of the Grant Agreement (either directly or through an accession form), which are fully responsible towards the Granting Authority for implementing it and for complying with all its obligations. “Competent Authority” (CA) means the central authority of a Member State competent for health/specific (public) health topic or any other authority to which that competence has been conferred; it shall also include, where appropriate, the corresponding authority of a third country. A Competent Authority can also be one at regional level, depending on the governance structure of the Member State/third country. “Chairperson” or “Chair” is the person from the Consortium Body assigned a role to lead that Consortium Body’s meeting. “Confidential Information” or “Sensitive Information” is the information: © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 8 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025  oral or written, communicated by a Consortium Member ("Issuing Party") to the other Consortium Member ("Receiving Party") for the purpose of executing the Joint Action, including, but not limited to: information of a scientific, technical, financial, legal, tax and commercial nature, business models and strategies, ideas, inventions, concepts, business plans, new products, contracts, know-how, logo design, technologies, names of potential clients and partners, projects and operations of any nature proposed or under study, reports, instructions, recommendations, drawings, plans, market projections and data, together with analyses and working documents, compilations, comparisons, studies and, in general, all information that the Parties transmit to each other, whether prior to or after the signing of this Consortium Agreement.  which has been explicitly marked as “confidential” or “sensitive” at the time of disclosure by the Disclosing Party, or when disclosed orally has been identified as "confidential" or "sensitive" at the time of disclosure and has been confirmed and designated in writing within fifteen (15) calendar days from oral disclosure at the latest as "confidential" or "sensitive" information by the Disclosing Party. “Consortium Agreement” means this document and its attachments, including any amendments thereto as well as any other document incorporated therein by reference, which are integral parts of this Consortium Agreement. “Consortium Body” or “Consortium Bodies” means any management body described in Section 6. (Governance Structure) of this Consortium Agreement. “Consortium Plan” means the description of the Action (Annex 1 of the Grant Agreement) and the related agreed budget (Annex 2 of the Grant Agreement) as first defined in the Grant Agreement and which may be updated by the General Assembly. "Data" means the information which is part of a Consortium Member's Background included in Annex 1 of this Consortium Agreement or which is generated, collected, and used within the Joint Action as "results". "Personal Data" means "any information relating to an identified or identifiable natural person (data subject); an identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person." "Data Protection Laws" means all applicable legislation concerning the protection of personal data, including the Regulation (EU) 2016/679 Of The European Parliament And Of The Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (hereinafter referred to as General Data Protection Regulation or "GDPR"), any other data protection legislation applicable to the Joint Action, as well as the binding orders of data protection authorities. “Defaulting Party” means a Party which the majority of the General Assembly has declared to be in breach of this Consortium Agreement and/or the Grant Agreement as specified in Section 4.2 of this Consortium Agreement. "Dissemination" means the public disclosure of the Results by any appropriate means (other than resulting from protecting or exploiting the Results), including by scientific publications in any medium. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 9 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 "Exploitation" means using Results in developing, creating and marketing or improving a product, process, or service, or shaping a policy that could have a positive impact on the public's quality of life. “Effective Date” means September 1st, the day from which the Grant Agreement’s obligations enter into force, and which marks the start date of the Joint Action. “Fair and Reasonable conditions” means appropriate conditions, including possible financial terms or royalty-free conditions, taking into account the specific circumstances of the request for access, for example the actual or potential value of the Results or Background to which access is requested and/or the scope, duration or other characteristics of the exploitation envisaged. “Force Majeure” means any one or more events beyond the reasonable control of the relevant Party which occur after the date of signing of this Consortium Agreement, were not reasonably foreseeable at the time of signing of this Consortium Agreement, and the effects of which are not capable of being overcome without unreasonable expense and/or unreasonable loss of time to the Party concerned provided such Party continues to follow all laws and regulations applicable to its performance under this Agreement to the extent is possible. Force Majeure events shall include (without limitation) war, civil unrest, acts of government, natural disasters, exceptional weather conditions, breakdown or general unavailability of transport facilities, accidents, fire, explosions, and general shortages of energy. Notwithstanding the foregoing, article 35 of the Grant Agreement and its annotations shall apply in any interpretation of whether specific circumstances shall constitute an event of Force Majeure. “General Assembly” or “GA” is the ultimate decision-making Consortium Body described in details in Section 6 of this Consortium Agreement “Granting Authority” means the body awarding the grant for the Project. “Intellectual Property Rights” or IPR(s) means: patents, patent applications and other statutory rights in inventions; copyrights (including without limitation copyrights in Software); registered design rights, applications for registered design rights, unregistered design rights and other statutory rights in designs; and other similar or equivalent forms of statutory protection, wherever in the world arising or available, but excluding rights in Confidential Information and/or trade secrets. “Internal Financial Report” or “IFR” is financial report submitted to the Coordinator by each Beneficiary and on behalf of themselves and their Affiliated Entities’ pursuant to Section 7 of this Consortium Agreement. “Joint Action” or “Project” means the Project entitled “Joint Action Prevention oriented RIghts- based approach to Support Mental health in vulnerable population groups “ (PRIMS) funded by the Granting Authority under Grant Agreement 101219450 whose objectives are described in Annex 1 of Grant Agreement. “Needed” means: For the implementation of the Project: Access Rights are Needed if, without the grant of such Access Rights, carrying out the tasks assigned to the recipient Party would be technically or legally impossible, significantly delayed, or require significant additional financial or human resources. For Exploitation of own Results: © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 10 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Access Rights are Needed if, without the grant of such Access Rights, the Exploitation of own Results would be technically or legally impossible. “Open Access” means a free online access for the end user to the results of research derived from the Joint Action funded by the EU4Health Programme 2021-2027 in accordance with Article 14 and Article 39(3) of the Horizon Europe Regulation (article 2.4º). “Portal” or “Portal Participant Register” or “EU Funding & Tenders Portal”. Electronic portal and exchange system managed by the European Commission and used by itself and other EU institutions, bodies, offices or agencies for the management of their funding programmes (grants, procurements, prizes, etc.) and by project Coordinator and Beneficiaries to exchange information with the European Commission and/or the Granting Authority. “Recipient” means a Consortium Member receiving Confidential Information from another Party for the purpose of implementing the Joint Action, and whose obligations are described in Section 10.2 of this Consortium Agreement. “Representative” or Representatives” is an individual representing or/and performing work on behalf of their institution (Party) in a Consortium Body. "Results" means any tangible or intangible output of the Action, such as data, systems, knowledge, or information, that is generated in the Action to which access may be permitted in the form of scientific publications, data or other results and processes derived from engineering, such as computer programs, algorithms, protocols and electronic notebooks (Article 2.22ºof Horizon Europe Regulation), whatever its form or nature, whether or not it can be protected, as well as any rights attached to it, including intellectual property rights. These results encompass all documents, regardless of their content and medium, produced by the Consortium Members, along with the developed software tools. These results include, but are not limited to, technical reports, project guidelines, software and manuals; the finalized versions of the certification process, the maturity model, the governance model for the Action portal; training modules and e-learning courses; workshops and seminar materials; periodic progress reports; and evaluation and impact assessment reports. As a general rule, open access to research outputs such as software, models, algorithms, workflows, protocols, simulations, electronic notebooks and others is not required but Parties will consider it recommendable according to the Horizon Europe Programme Guide. “Software” means sequences of instructions to carry out a process in, or convertible into, a form executable by a computer and fixed in any tangible medium of expression. “Work Package” or “WP”: Sub-division of work implementation of the Joint Action described in Annex 1 of the Grant Agreement. “Work Package Leader” or “WPL” means a representative of the Party appointed to lead a work package according to Annex 1 of the Grant Agreement, who shall coordinate the completion of activities for the tasks in the relevant work package. "Work Package Co-Leader" supports the Work Package Leader in their tasks and may act as Work Package Leader when necessary. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 11 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 2 Purpose The purpose of this Consortium Agreement is to specify with respect to the Project the relationship among the Parties, in particular concerning the organisation of the work between the Parties, the management of the Project and the rights and obligations of the Parties concerning inter alia liability, Access Rights and dispute resolution. 3 Entry into force, duration and termination 3.1 Entry into force An entity becomes a Party to this Consortium Agreement upon signature of this Consortium Agreement by a duly authorised representative. This Consortium Agreement shall take effect as of the 1st day of September, 2025 (the “Effective Date”), as identified at the beginning of this Consortium Agreement. An entity becomes a new Party to the Consortium Agreement upon signature of the accession document (Attachment 2) by the new Party and the Coordinator. Such accession shall have effect from the date identified in the accession document. 3.2 Duration and termination This Consortium Agreement shall continue in full force for 36 months and effect until complete fulfilment of all obligations undertaken by the Parties under the Grant Agreement and under this Consortium Agreement. For avoidance of doubt, the close of the Project is expected to end 30 August 2028 absent any further extension which will be communicated in advance between the Parties and formalized in writing. However, this Consortium Agreement or the participation of one or more Parties to it may be terminated in accordance with the terms of this Consortium Agreement. If  the Grant Agreement is not signed by the Granting Authority or a Beneficiary, or  the Grant Agreement is terminated, or  a Beneficiary does not sign the accession form to the Grant Agreement, or  a Beneficiary's participation in the Grant Agreement is terminated, this Consortium Agreement shall automatically terminate in respect of the Party/ies concerned, subject to the provisions surviving the expiration or termination under Section 3.3 of this Consortium Agreement. If Associated Partner´s participation in the Project is terminated, its participation in this Consortium Agreement may be terminated subject to the provisions surviving the expiration or termination under this Consortium Agreement (Section 3.3 and Section 4.6). 3.3 Survival of rights and obligations The provisions relating to Access Rights, Dissemination and confidentiality, for the time period mentioned therein, as well as for liability, applicable law and settlement of disputes shall survive the expiration or termination of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 12 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Termination shall not affect any rights or obligations of a Party leaving the Project incurred prior to the date of termination, unless otherwise agreed between the General Assembly and the leaving Party. This includes the obligation to provide all necessary input, deliverables and documents for the period of its participation. 4 Responsibilities of Parties 4.1 General principles and Specific responsibilities of Beneficiaries a. General principles Each Party undertakes to take part in the efficient implementation of the Project, and to cooperate, perform and fulfil, promptly and on time, all of its obligations under the Grant Agreement and this Consortium Agreement as may be reasonably required from it and in a manner of good faith as prescribed by Belgian law. Each Party undertakes to notify promptly the Granting Authority, the Coordinator and the other Parties, in accordance with the governance structure of the Project, of any significant information, fact, problem or delay likely to affect the Project. Each Party shall promptly provide all information reasonably required by a Consortium Body, the Coordinator or by a Work Package Leader to carry out its tasks. Moreover, the Coordinator and the Beneficiaries shall responsibly manage the access of its employees to the EU Funding & Tenders Portal. Each Beneficiary shall ensure that its obligations under the Grant Agreement and this Consortium Agreement apply “mutatis mutandis” to its Affiliated Entities, if any, and shall share all relevant Project information, including but not limited to the Grant Agreement and this Consortium Agreement, with them. The Beneficiary to which the Associated Partner is linked shall ensure: - the proper implementation of the tasks proceeded by the Associated Partner (proper quality, timely delivery, etc), - that the Associated Partner complies with certain obligations listed in Article 9.1 of the Grant Agreement, - that the bodies mentioned in Article 25 of the Grant Agreement (e.g. Granting Authority, the European Court of Auditors, the European Anti-Fraud Office) can exercise their rights towards their Associated Partner, - that obligations above are accepted by the Associated Partner in written. Each Party shall take reasonable measures to ensure the accuracy of any information or materials it supplies to the other Parties. b) Specific responsibilities of Beneficiaries Beneficiaries being signatories of the Grant Agreement (by having signed the accession form, see Annex 3 of the Grant Agreement), are fully responsible towards the Granting Authority for implementing the Grant Agreement and for complying with all its own obligations. Each Beneficiary remains solely responsible towards the Granting Authority for the costs declared on its own behalf and also that of its Affiliated Entities, including the transfer of any © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 13 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 remaining funds from the Affiliated Entities Beneficiaries must: - Keep information stored in the Portal Participant Register (in the electronic exchange system) up to date (Article 19.2 of the Grant Agreement). - lnform the Coordinator immediately of any events or circumstances Notwithstanding the provisions of this Consortium Agreement, in accordance with Articles 7 and 8 of the Grant Agreement, each Beneficiary shall be responsible to ensure compliance by its Affiliated Entities with the terms of the Grant Agreement. Where reference to allocated work to be performed by a Beneficiary is made in the Grant Agreement, it shall be understood as referring to allocated work to be performed by the Beneficiary or any of its Affiliated Entities. - Likely to significantly affect or delay the implementation of the Action (Article 19.3 of the Grant Agreement). - Discuss any unforeseen activities requiring an amendment, first with the WP leader, thereafter with the Coordinator, who will bring the matter to the General Assembly (according to 6.) if an amendment is deemed necessary. - Submit to the Coordinator in good time: o The financial statements for itself and its Affiliated Entities and any information needed to draft all requested reports under article 21 of the Grant Agreement; o If required, certificates on the financial statements (Article 24 of the Grant Agreement); o The Internal Financial Reports according to the schedule defined in Article 7 of this Consortium Agreement; o Any other document(s) or information required by the Granting Authority under the Grant Agreement. - Submit via the Portal data information related to the participation of their Affiliated Entities. 4.2 Breach In the event that the General Assembly identifies a breach by a Party of its obligations under this Consortium Agreement or the Grant Agreement (e.g. improper implementation of the Project), the Coordinator or, if the Coordinator is in breach of its obligations, the Party appointed by the General Assembly, will give formal notice to such Party requiring that such breach will be remedied within 30 calendar days from the date of receipt of the written notice by the Party. If such breach is substantial and is not remedied within that period or is not capable of remedy, the General Assembly may decide to declare the Party to be a Defaulting Party and to decide on the consequences thereof which may include termination of its participation. Breaches by Affiliated Entities shall be handled in the same manner as breaches by Beneficiaries. Recovery of undue amounts from Affiliated Entities shall be handled through the Beneficiaries. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 14 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 4.3 Involvement of Third Parties A Party that enters into a subcontract or otherwise involves Third Parties (including but not limited to Affiliated Entities or other Participants) in the Project remains responsible for carrying out its relevant part of the Project and for such Third Party’s compliance with the provisions of this Consortium Agreement and of the Grant Agreement. Such Party has to ensure that the involvement of Third Parties does not affect the rights and obligations of the other Parties under this Consortium Agreement and the Grant Agreement. To that end, it is good practice for a Party that involves Affiliated Entities or Third Parties to conclude a written contract with those Affiliated Entities or Third Parties that ensures compliance with the provisions of the Grant Agreement and this Consortium Agreement, and to inform the Coordinator accordingly of the conclusion of this contract. All Parties must comply with the applicable national law on public procurement to subcontract Third Parties. All procurement procedures must comply with the principles of EU legislation, must be supported by documentary evidence and presented on first request of Coordinator or Granting Authority 4.4 Specific responsibilities regarding data protection Where necessary and applicable, the Parties shall reasonably cooperate in order to enable one another to fulfil legal obligations arising under applicable data protection laws (the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data and relevant national data protection law applicable to said Party) within the scope of the performance and administration of the Project and of this Consortium Agreement. The Consortium Members undertake not to commence the Joint Action until all mandatory approvals have been obtained and the legally required documents under applicable data protection laws have been duly executed through the relevant legal instruments. To this end, and without prejudice to any other obligations that may arise from applicable regulations, a Data Transfer Agreement, a Data Access Agreement, or an agreement governing the relationship between data controllers and data processors (data controller - data processor), or between joint controllers (co-data controller), or between data controllers (data controller - data controller), shall be executed, as appropriate as specified in clause 4.6. In particular, the Parties shall, where necessary, conclude a separate data processing, data sharing and/or joint controller agreement before any data processing or data sharing takes place. 4.5 Specific responsibilities regarding reporting and implementation 4.5.1 Internal Progress Reports The Parties commit to continuously provide information on the progress of the implementation of the work packages. In particular: 1. At least 7 calendar days prior to each Executive Board (EB) meeting, each Work Package (WP) Leader shall complete a progress update using a standardized template provided by the Coordinator. This update will be presented and discussed during the EB meeting. 2. Every 6 months, and whenever a periodic report is not due, an Internal Report shall be prepared. This report will consist of: © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 15 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025  A technical section, to be completed by the respective WP Leaders, detailing the progress and status of each WP.  A financial section, to be completed by all Beneficiaries, providing updated financial information relevant to the reporting period. These reports shall enable effective monitoring of the project’s implementation, including assessment of the status or completion of each work package, and may include performance indicators as defined in Annex 1 of the Grant Agreement, if applicable. 4.5.2 Proper implementation Each Party shall perform its tasks in accordance with the Consortium Plan and contribute to the completion of the work package. If a work package cannot be completed, the Parties must collaborate to propose an amendment of the Grant Agreement for that work package via an alternative solution. 4.5.3 Termination reports A leaving Party shall issue a termination report to the Executive Board (EB) in accordance with Article 32 of the Grant Agreement on the activities implemented by it and completion of its work share in the work packages it is involved in for the period until its termination takes effect. 4.5.4 Consequences of non-compliance Improper reporting or implementation of the Project may lead to a breach procedure and termination of a Party’s participation according to Section 4.2 of this Consortium Agreement. The Parties are aware, that their implementation may affect the completion of tasks or work packages by other Parties and that improper implementation or reporting can lead to liability in accordance with Section 5 of this Consortium Agreement, e.g. in case of reduction or recovery of funding by the Granting Authority. 4.6 Specific responsibilities for Associated Partners For the avoidance of doubt, the Associated Partner(s) do(es) not sign the Grant Agreement and do(es) not receive funding from the Granting Authority and therefore do(es) not have a right to charge costs or claim contributions from the Granting Authority. Associated Partner(s) must ensure its/their own funding for the implementation of the Project. However, certain terms and conditions of the Grant Agreement and its Annexes are applicable to the Associated Partner(s). The Coordinator will share a copy of the signed Grant Agreement and information on any amendments with the Associated Partner(s). The Associated Partner(s) hereby commit(s) to implement the Project tasks attributed to it/them in Annex 1 of the Grant Agreement. In addition, the Associated Partner(s) hereby commit(s) especially to the following articles of the Grant Agreement and related regulations of Annex 5: - Proper implementation of the action (Article 11) - Conflicts of interest (Article 12) - Confidentiality and security (Article 13) - Ethics and values (Article 14) - Visibility (Article 17.2) - Specific rules for carrying out the action (Article 18) - General Information obligations (Article 19) - Record-keeping (Article 20) © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 16 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 The Associated Partner(s) support(s) the Beneficiaries regarding their exploitation, dissemination and Open Science obligations and commit(s) to contribute to the technical and continuous reporting during and after the implementation of the Project. Furthermore, the Associated Partner(s) hereby explicitly agree to cooperate with and grant access to bodies according to Article 25 of the Grant Agreement (the Granting Authority, the European Anti-Fraud Office (OLAF), the European Public Prosecutor’s Office (EPPO), the European Court of Auditors (ECA)), so that these bodies can carry out checks, reviews, audits and investigations also towards the Associated Partner(s). Any Associated Partner from a non-EU country undertakes to comply additionally with any other obligation arising from Art. 10.1 of the Grant Agreement. In case of termination or being declared a Defaulting Party, an Associated Partner shall, within the limits specified in section 5.2 of this Consortium Agreement, bear any reasonable and justifiable costs occurring to the other Parties for performing this Associated Partners tasks and the costs for additional efforts necessary to implement the Project. Moreover, an Associated Partner is obliged to indemnify the other Parties for any claim of the Granting Authority against them, caused by this Associated Partner´s actions or omissions during Grant Agreement preparation, Project implementation or after Project end. Regarding such claims the Associated Partner´s special liability is limited to once the amount of its total estimated costs as indicated in Annex 1 of the Grant Agreement. Should the Associated Partner(s) be obliged to sign a separate agreement concerning its funding for the Project, it is the responsibility of the Associated Partner to ensure such agreement is not in conflict with this Consortium Agreement. 4.7 Involvement of Third Parties A Consortium Member that enters a subcontract or otherwise involves third parties in the Joint Action remains responsible for carrying out its relevant part of the Project and for such third party's compliance with the provisions of this Consortium Agreement and of the Grant Agreement. Such Consortium Member must ensure that the involvement of third parties does not affect the rights and obligations of the Consortium Members under the Consortium Agreement and the Grant Agreement. 5 Liability towards each other To the best of its knowledge and belief, the Parties certify that the advice, material, works, information, services and deliverables provided or given by its employees, students, agents or appointees who work on the Project are in good condition and are not infringing on any third party rights. 5.1 No warranties In respect of any information or materials (incl. Results and Background) supplied by one Party to another under the Project, no warranty or representation of any kind is made, given or implied as to the sufficiency or fitness for purpose Therefore, © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 17 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025  the recipient Party shall in all cases be entirely and solely liable for the use to which it puts such information and materials, and  no Party granting Access Rights shall be liable in case of infringement of proprietary rights of a Third Party resulting from any other Party (or its entities under the same control) exercising its Access Rights. 5.2 Limitations of contractual liability To the extent legally permissible, no Party shall be responsible to any other Party for any indirect or consequential loss or similar damage such as, but not limited to, loss of profit, loss of revenue or loss of contracts, except in case of breach of confidentiality. A Party’s general aggregate liability towards the other Parties collectively shall be limited to once the Beneficiary’s share of the total costs of the Project as identified in Annex 2 of the Grant Agreement and in case of Associated Partners to once the amount of its total estimated costs as indicated in Annex 1 of the Grant Agreement. The limitation to the Beneficiaries’ general aggregate liability also apply to Affiliated Entities (unless prohibited by law) Each Party will be responsible for its own negligent acts or omissions and the negligent acts or omissions of its employees, officers, or directors in the performance of the Project and the administration of this Agreement, to the extent allowed by law. A Party’s or Associated Partner’s liability shall not be limited under either of the two foregoing paragraphs to the extent such damage was caused by a wilful act or gross negligence or to the extent that such limitation is not permitted by law. 5.3 Damage caused to Third Parties Each Party shall be solely liable for any loss, damage or injury to Third Parties resulting from and to the extent caused by the negligent acts or omissions of a Party during the performance of the said Party’s obligations by it or on its behalf under this Consortium Agreement or from its use of Results or Background. 5.4 Force Majeure No Party shall be considered to be in breach of this Consortium Agreement if it is prevented from fulfilling its obligations under the Consortium Agreement by Force Majeure. Each Party will notify the General Assembly of any Force Majeure without undue delay. If the consequences of Force Majeure for the Project are not overcome within 6 weeks after such notice, the transfer of tasks - if any - shall be decided by the General Assembly. 5.5 Compliance Subject to the foregoing liability exclusions and limitation, each Party shall be legally accountable to ensure that its work in the Project complies fully with all applicable local, national, European and international laws, regulations and guidelines which are effective during the period of the Project, including those governing health and safety, Data protection, and where relevant, the use of human or animal subjects and good clinical practice (including national legislation implementing the Parliament’s Directive 2001/20/EC on good clinical practice). © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 18 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 In this regard, each Party shall follow the confidentiality rules in accordance with Section 10 of this Consortium Agreement. Each Consortium Member shall secure all necessary approvals from the relevant governmental, legal or ethics committees before undertaking any part of the Joint Action requiring governmental, legal regulations or ethics committee approval and shall, if required, obtain properly signed informed consent and acknowledgement forms from any human subjects, or their legal guardians, whose data will be under management of this Joint Action. Where any part of the Joint Action takes place at the data provider institution, the Consortium Member involved shall first obtain all necessary approvals and agreements from that institution in compliance with the country or regional law. 6 Governance structure 6.1 General structure The organisational structure of the consortium shall comprise the following Consortium Bodies (figure 1): - The Coordination Team as the entity acting as the intermediary between the Parties and the Granting Authority. The Coordinator shall, in addition to its responsibilities as a Party, perform the tasks assigned to it as described in the Grant Agreement and this Consortium Agreement. - The Executive Board (EB) as the supervisory body for the execution of the Project, which shall report to and be accountable to the General Assembly. The EB should be composed by the Coordination Team and by the Work Packages Leaders and Co-leaders. - The General Assembly (GA) as the ultimate decision-making body of the consortium. The GA shall be composed by at least one representative from each Beneficiary and Affiliated Entity. - The Advisory Board (AB) as a body composed of experts having insight into different aspects of the Joint Action’s activities, with the aim of supporting the Project in maximising its impact. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 19 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Figure 1. PRISM Governance Structure The organisational structure of the consortium shall also comprise the following functions: - The Coordinator as the legal entity acting as the intermediary between the Parties and the Granting Authority. The Coordinator shall, in addition to its responsibilities as a Party, perform the tasks assigned to it as described in the Grant Agreement and this Consortium Agreement. The Coordinator will rely on the Coordination Team, composed by the Scientific Coordinator, Two Project Managers and the Financial Manager. - The Work Package (WP) leaders and co-leaders are responsible for the timely implementation of their respective work packages to ensure the required objectives and results are achieved. 6.2 Operational procedures for the General Assembly and Executive Board 6.2.1 Representation in meetings  Any Party which is appointed to take part in a General Assembly and Executive Board shall designate one representative (hereinafter referred to as "Member") should be present or represented at any meeting;  may appoint a substitute or a proxy to attend and vote at any meeting;  and shall participate in a cooperative manner in the meetings. 6.2.2 Preparation and organisation of meetings 6.2.2.1 Convening meetings The chairperson of a Consortium Body shall convene meetings of that Consortium Body. Ordinary meeting Extraordinary meeting General Assembly At least once a year At any time upon request of the Executive Board or 1/3 of the Members of the General Assembly Executive Board At least once a month At any time upon request of any member of the Executive Board or of the Coordinator 6.2.2.2 Notice of a meeting The chairperson of a Consortium Body shall give written notice of a meeting to each Member of that Consortium Body as soon as possible and no later than the minimum number of days preceding the meeting as indicated below. Ordinary meeting Extraordinary meeting General Assembly 60 calendar days 10 calendar days © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 20 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Executive Board 14 calendar days 7 calendar days 6.2.2.3 Sending the agenda The chairperson of a Consortium Body shall prepare and send each Member of that Consortium Body an agenda no later than the minimum number of days preceding the meeting as indicated below. Ordinary meeting Extraordinary meeting General Assembly 14 calendar days 7 calendar days Executive Board 7 calendar days 7 calendar days 6.2.2.4 Adding agenda items Any agenda item requiring a decision by the Members of a Consortium Body must be identified as such on the agenda. Any Member of a Consortium Body may add an item to the original agenda by written notice to all of the other Members of that Consortium Body up to the minimum number of days preceding the meeting as indicated below. General Assembly 7 calendar days, 5 calendar days for an extraordinary meeting Executive Board 2 calendar days 6.2.2.5 Meeting modalities Meetings of each Consortium Body may also be held by tele- or videoconference or other telecommunication means. 6.2.2.6 Entry into force of decisions Decisions will only be binding once the relevant part of the minutes has been accepted according to Section 6.2.5. 6.2.2.7 Decisions without a meeting Any decision may also be taken without a meeting if the Coordinator circulates to all Members of the Consortium Body a written document, which is then agreed by the defined majority (see Section 6.2.3) of all Members of the Consortium Body. Such document shall include the deadline for responses. Decisions taken without a meeting shall be considered as accepted if, within the period set out in article 6.2.4, no Member has sent an objection in writing to the chairperson. The decisions will be binding after © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 21 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 the chairperson sends to all Members of the Consortium Body and to the Coordinator a written notification of this acceptance. The Coordinator shall inform all the Members of the outcome of the vote. A veto according to Section 6.2.4 may be submitted up to 15 calendar days after receipt of this information. Without any objection received within this period, the decision/outcome of the vote shall be considered as accepted. In cases of severe dispute, the Coordinator shall refer the decision to a regular or extraordinary meeting as appropriate. The decision will be binding after the Coordinator sends a notification to all Members. The Coordinator will keep records of the votes and make them available to the Parties on request. 6.2.3 Voting rules and quorum 6.2.3.1 Quorum Consortium Body shall not deliberate and decide validly in meetings unless two-thirds (2/3) of its Members are present or represented (quorum). If the quorum is not reached, the chairperson of the Consortium Body shall convene another ordinary meeting within 15 calendar days. If in this meeting the quorum is not reached once more, the chairperson shall convene an extraordinary meeting which shall be entitled to decide even if less than the quorum of Members is present or represented. 6.2.3.2 Voting rules Each Member of a Consortium Body present or represented in the meeting shall have one vote. A Party which the General Assembly has declared according to Section 4.2 to be a Defaulting Party may not vote. 6.2.3.3 Validity of decisions Decisions shall be taken by a majority of two-thirds (2/3) of the votes cast. 6.2.4 Veto rights A Party which can show that its own work, time for performance, costs, liabilities, intellectual property rights or other legitimate interests would be severely affected by a decision of the Consortium Body may exercise a veto with respect to the corresponding decision or relevant part of the decision. When the decision is foreseen on the original agenda, a Party may only veto such a decision during the meeting. When a decision has been taken on a new item added to the agenda before or during the meeting, a Party may veto such decision during the meeting or within 15 calendar days after receipt of the draft minutes of the meeting. When a decision has been taken without a meeting a Party may veto such decision within 15 calendar days after receipt of the written notice by the chairperson of the outcome of the vote. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 22 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 In case of exercise of veto, the Members of the related Consortium Body shall make every effort to resolve the matter which occasioned the veto to the general satisfaction of all Parties. A Party may neither veto decisions relating to its identification to be in breach of its obligations nor to its identification as a Defaulting Party. The Defaulting Party may not veto decisions relating to its participation and termination in the consortium or the consequences of them. A Party requesting to leave the consortium may not veto decisions relating thereto. 6.2.5 Minutes of meetings The chairperson of a Consortium Body shall be responsible for taking minutes of each meeting which shall be the formal record of all decisions taken. He/she shall send draft minutes to all Members within 14 calendar days of the meeting. The minutes shall be considered as accepted if, within 14 calendar days from receipt, no Member has sent an objection to the chairperson with respect to the accuracy of the draft minutes by written notice. The chairperson shall send the accepted minutes to all the Parties, and to the Coordinator, who shall retain copies of them. 6.3 Specific operational procedures for the Consortium Bodies 6.3.1 General Assembly In addition to the rules described in Section 6.2, the following rules apply: 6.3.1.1 Members The General Assembly shall consist of one representative from each Beneficiary and Affiliated Entity (hereinafter General Assembly Member). Each General Assembly Member shall be deemed to be duly authorised to deliberate, negotiate and decide on all matters listed in Section 6.3.1.3 of this Consortium Agreement. Regarding unanimity or majority decisions, only Members with voting rights regarding the item are taken into account. 6.3.1.2 Chair The Coordinator shall chair, together with a vice-chair, all meetings of the General Assembly, unless decided otherwise in a meeting of the General Assembly. 6.3.1.3 Decisions The General Assembly shall be free to act on its own initiative to formulate proposals and take decisions in accordance with the procedures set out herein. In addition, all proposals made by the Executive Board shall also be considered and decided upon by the General Assembly. The following decisions shall be taken by the General Assembly: Content, finances and intellectual property rights: © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 23 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025  Proposals for changes to Annexes 1 and 2 of the Grant Agreement to be agreed by the Granting Authority  Changes to the Consortium Plan  Modifications or withdrawal of Background in Attachment 1 (Background Included)  Additions to Attachment 3 (List of Third Parties for simplified transfer according to Section 8.3.2)  Additions to Attachment 4 (Identified Entities under the same control) Evolution of the consortium:  Entry of a new Party to the Project and approval of the settlement on the conditions of the accession of such a new Party  Withdrawal of a Party from the Project and the approval of the settlement on the conditions of the withdrawal  Proposal to the Granting Authority for a change of the Coordinator  Proposal to the Granting Authority for suspension of all or part of the Project  Proposal to the Granting Authority for termination of the Project and the Consortium Agreement Breach, defaulting party status and litigation:  Identification of a breach by a Party of its obligations under this Consortium Agreement or the Grant Agreement  Declaration of a Party to be a Defaulting Party  Remedies to be performed by a Defaulting Party  Termination of a Defaulting Party’s participation in the consortium and measures relating thereto  Steps to be taken for litigation purposes and the coverage of litigation costs in case of joint claims of the parties of the consortium against a Party (Section 4.2, Section 7.1.4) The Parties agree to abide by all decisions of the General Assembly. This does not prevent the Parties from exercising their veto rights, according to Section 6.2.4. or from submitting a dispute to resolution in accordance with the provisions of Settlement of disputes in Section 11.8. 6.3.2 Executive Board (EB) In addition to the rules in Section 6.2, the following rules shall apply: 6.3.2.1 Members The Executive Board shall consist of representatives of the Coordination Team and one representative of the Work Packages Leaders and co-Leaders, as a decision making body on daily running of the project, with prerogatives regarding minor updates, and effort/budget re-assignment as well as conflict resolution. 6.3.2.2 Chair The Coordinator shall chair all meetings of the Executive Board, unless decided otherwise by a majority of two-thirds. 6.3.2.3 Minutes of meetings Minutes of the Executive Board meetings, once accepted, shall be sent by the Chair to the General Assembly Members for information. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 24 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 6.3.2.4 Tasks The Executive Board members commit themselves to undertake their tasks in an unbiased way. The Executive Board is the operational body that supports the Coordinator in the day-to-day scientific and technical coordination of the Project. The Executive Board shall also ensure the coherence and the integration of all the WPs and tasks of the Project; it ensures cross-cutting discussion and synergies. The Executive Board shall: a) propose all operational decisions required for the implementation of the Project; b) prepare the meetings, propose decisions and prepare the agenda of the General Assembly according to Section 6.3.1 c) properly execute and implement the decisions of the General Assembly; d) collaborate with all Parties of the Consortium for the planning, implementation and reporting of the Project; e) monitor the effective and efficient implementation of the Project and ensure alignment of activities between the WPs and progress towards common goal of success in the Project, f) collect information at least every 6 months on the progress of the Project, examine that information to assess the compliance of the Project with the Consortium Plan and, if necessary, propose modifications of the Consortium Plan to the General Assembly g) support the Coordinator in preparing meetings with the Granting Authority and in preparing related data and deliverables; h) perform quality-check and approve deliverables before submission to the Granting Authority; i) monitor the creation of Results and their ownership and any protection measures, j) prepare the content and timing of press releases and joint publications by the consortium or proposed by the Granting Authority in respect of the procedures of the Grant Agreement Article and Annex 5 Section “Communication, Dissemination, Open Science and Visibility” and of Section Results of this Consortium Agreement. In the case of abolished tasks as a result of a decision of the General Assembly, the Executive Board shall advise the General Assembly on ways to rearrange tasks and budgets of the Parties concerned. Such rearrangement shall take into consideration any prior legitimate commitments which cannot be cancelled. The Executive Board shall seek a consensus among the Parties. 6.4 Coordinator 6.4.1 Role of the Coordinator The Coordinator shall be the intermediary between the Parties and the Granting Authority and shall perform all tasks assigned to it as described in the Grant Agreement and in this Consortium Agreement. 6.4.2 Responsibilities In particular, the Coordinator shall be responsible for:  monitoring compliance by the Parties with their obligations under this Consortium Agreement and the Grant Agreement © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 25 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025  keeping the address list of Members and other contact persons updated and available  collecting, reviewing to verify consistency and submitting reports, other deliverables (including financial statements and related certification) and specific requested documents to the Granting Authority  transmitting promptly documents and information connected with the Project to any other Party concerned  administering the financial contribution of the Granting Authority and fulfilling the financial tasks described in Section 7.2  providing, upon request, the Parties with official copies or originals of documents that are in the sole possession of the Coordinator when such copies or originals are necessary for the Parties to present claims.  providing a copy of the Grant Agreement and its Annexes to the Associated Partners. If one or more of the Parties is late in submission of any Project deliverable, the Coordinator may nevertheless submit the other Parties’ Project deliverables and all other documents required by the Grant Agreement to the Granting Authority in time. 6.4.3 Change of Coordinator If the Coordinator fails in its coordination tasks, the General Assembly may propose to the Granting Authority to change the Coordinator. 6.4.4 Declarations of the Coordinator The Coordinator shall not be entitled to act or to make legally binding declarations on behalf of any other Party or of the consortium, unless explicitly stated otherwise in the Grant Agreement or this Consortium Agreement. 6.4.5 Scope of action of the Coordinator The Coordinator shall not enlarge its role beyond the tasks specified in this Consortium Agreement and in the Grant Agreement. 6.5 Coordination team BIOSISTEMAK assumes the role of JA PRISM Coordinator, being the organization representing the Consortium. It is responsible for the achievement of the Project goals and the contractual obligations towards the European Commission, and provides global scientific and technical leadership, quality assurance policy and overall coordination of the joint action. The Coordinator Team is formed by the JA Coordinator supported by the Scientific Coordinator, the Project Managers (PM) and the Financial Manager. 6.6 Work Package Lead (WPL) The WPL is performed by the correspondent Lead Beneficiary (LB) included in the Grant Agreement – Annex 1 PART A, who is supported by a co-Lead Beneficiary. They have the responsibility for day-to- day management and coordination of the activities included in their respective work packages as defined in the work plan, implement solutions for problems, supervise Task Leaders, produce the corresponding deliverables, identify risks as early as possible and follow them up, and report to the Project Managers about the progress achieved against that planned. They are able to raise proposals to the EB regarding effort and budget redistribution, and re-assignment of roles and responsibilities within their respective WPs. WP participants meet at least once a month via tele- or web-conferencing. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 26 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 6.7 Advisory Board (AB) The Advisory Board (AB) will consist of international experts in the field of mental health. The board will provide expert insight in different aspects of the Project activities, will support the development of policy- oriented recommendations and will promote their widespread dissemination. Additionally, the AB will encompass individuals with expertise in transversal and intersectional aspects, including equity, cultural, and ethnic diversity. Furthermore, gender and geographic balance will be taken into consideration during the selection process. The AB will be coordinated by the Scientific Coordinator, supported by the Coordination Team. Its task is to strengthen the scientific quality of work conducted within the Project and to contribute to optimal policy relevance. The AB will meet the EB during the GA meetings and additional dedicated meetings, virtual or face-to face, depending on specific needs or requirements. The Coordinator will propose standard Terms of Reference for the functioning of the AB. In case of any discrepancy between the provisions set forth in this Consortium Agreement and such Terms of Reference, the latter shall prevail. The Coordinator will ensure that a non-disclosure agreement is executed between all Parties and each AB member. By way of exception to Section 6.4.4 above, the Parties mandate the Coordinator to execute, in their name and on their behalf, a non-disclosure agreement (hereafter “NDA”) with each member of the AB, in order to protect Confidential Information disclosed by any of the Parties to any member of the AB either directly or through the Coordinator in the case where the concerned Party gave to the Coordinator its prior written approval for such disclosure. The NDA for the AB members is enclosed in Attachment 5. The mandate of the Coordinator comprises solely the execution of the NDA in Attachment 5. Its terms shall be not less stringent than those stipulated in this Consortium Agreement, and it shall be concluded no later than 30 calendar days after their nomination or before any confidential information will be exchanged/disclosed, whichever date is earlier. The Coordinator shall write the minutes of the AB meetings and submit them to the General Assembly. 7 Financial provisions Section 7 of the Consortium Agreement does not apply to Associated Partners as they do not receive any funding from this Joint Action. 7.1 General Principles 7.1.1 Distribution of Financial Contribution The financial contribution of the Granting Authority to the Project shall be distributed by the Coordinator according to:  the Consortium Plan  the approval of reports by the Granting Authority, and  the provisions of payment in Section 7.2. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 27 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 A Party shall only be able to receive funds after having duly signed the Accession Form to the Grant Agreement and this Consortium Agreement. 7.1.2 Justifying Costs A Beneficiary or an Affiliated Entity shall be funded only for its tasks carried out in accordance with the Consortium Plan. Each Beneficiary is responsible for the management and payment of its Third Parties and must ensure that they meet all the relevant obligations stipulated in the Grant Agreement. In accordance with its own usual accounting and management principles and practices, each Beneficiary shall be solely responsible for justifying its costs (and those of its Affiliated Entities, if any) with respect to the Project towards the Granting Authority. Neither the Coordinator nor any of the other Beneficiaries shall be in any way liable or responsible for such justification of costs towards the Granting Authority. Each Beneficiary will establish the necessary legal, administrative and operational arrangements with their Affiliated Entities to ensure the correct justification of the costs incurred. Neither the Coordinator nor any of the other Beneficiaries shall be in any way liable or responsible for such justification of costs towards the Granting Authority. Each Consortium Member should keep record of their cost’s justification in accordance with audit rules set up in article 25 of the Grant Agreement, for a duration of 5 years after the final payment made by the Granting Authority (Data Sheet Point 6 of the Grant Agreement). 7.1.3 Funding Principles A Beneficiary that spends less than its allocated share of the budget as set out in the Consortium Plan or – in case of reimbursement via unit costs - implements less units than foreseen in the Consortium Plan will be funded in accordance with its units/actual duly justified eligible costs only. A Beneficiary that spends more than its allocated share of the budget as set out in the Consortium Plan will be funded only in respect of duly justified eligible costs up to an amount not exceeding that share. 7.1.4 Return of excess financial payments A Beneficiary has received excess financial payment a) if the payment received from the Coordinator exceeds the amount declared or b) if a Beneficiary has received financial payments but, within the last year of the Project, its real Project costs fall significantly behind the costs it would be entitled to according to the Consortium Plan. In case a Beneficiary has received excess payment, the Beneficiary has to inform the Coordinator and return the relevant amount to the Coordinator without undue delay. In case no refund takes place within 30 days upon request for return of excess payment from the Coordinator, the Beneficiary is in substantial breach of the Consortium Agreement. Amounts which are not refunded by a breaching Beneficiary and which are not due to the Granting Authority, shall be apportioned by the Coordinator to the remaining Beneficiaries pro rata according to their share of total costs of the Project as identified in the Consortium Budget, until recovery from the breaching Beneficiary is possible. The General Assembly decides on any legal actions to be taken against the breaching Beneficiary according to Section 6.3. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 28 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 In case a Beneficiary earns any revenue that is deductible from the total funding as set out in the Consortium Plan, the deduction is only directed toward the Beneficiary earning such revenue. The other Parties’ financial share of the budget shall not be affected by one Beneficiary’s revenue. In case the relevant revenue is more than the allocated share of the Beneficiary as set out in the Consortium Plan, the Beneficiary shall reimburse the funding reduction suffered by other Beneficiaries. 7.1.5 Financial Consequences of the termination of the participation of a Party A Beneficiary leaving the consortium shall refund to the Coordinator any payments it has received except the amount of contribution accepted by the Granting Authority or another contributor. In addition, a Beneficiary declared to be a Defaulting Party shall, within the limits specified in Section 5.2 of this Consortium Agreement, bear any reasonable and justifiable additional costs occurring to the other Beneficiaries in order to perform the leaving Beneficiary´s task and necessary additional efforts to fulfil them as a consequence of the Beneficiary leaving the consortium. The General Assembly should agree on a procedure regarding additional costs which are not covered by the Defaulting Party or the Mutual Insurance Mechanism. 7.2 Payments 7.2.1 Principles Payments to Parties are the exclusive task of the Coordinator. In particular, the Coordinator shall:  notify the Beneficiary concerned promptly of the date and composition of the amount transferred to its bank account, giving the relevant references. The Coordinator will transfer to a Beneficiary the amounts due to the Beneficiary and to its Affiliated Entities. The Beneficiary is responsible to transfer the amounts due to its Affiliated Entities according to the information provided by the Coordinator;  perform diligently its tasks in the proper administration of any funds and in maintaining financial accounts;  undertake to keep the Granting Authority’s financial contribution to the Project separated from its normal business accounts, its own assets and property, except if the Coordinator is a Public Body or is not entitled to do so due to statutory legislation. With reference to Article 22 of the Grant Agreement, no Beneficiary shall before the end of the Project receive more than its allocated share of the maximum grant amount less the amounts retained by the Granting Authority for the Mutual Insurance Mechanism and for the final payment. 7.2.2 Payment mode The transfer of the initial pre-financing, interim payment and final payment to Beneficiaries will be handled in accordance with article 22 and article 7 of the Grant Agreement following this payment schedule: Pre-financing: The prefinancing payment from the Granting Authority will be transferred directly to the Beneficiaries concerned, without delay, but no later than forty-five (45) calendar days after receipt of the payment from the Granting Authority. The prefinancing payment is scheduled to be received before the effective date. Interim payment: The interim payment from the Granting Authority will be transferred directly to the Beneficiary/ies concerned, without delay, but no later than forty-five (45) calendar days after receipt of © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 29 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 the payment from the Granting Authority. The interim payment is scheduled to be received after the first reporting period: from month 1 to month 18. Final payment: The final payment from the Granting Authority will be transferred directly to the Beneficiary/ies concerned, without delay, but no later than forty-five (45) calendar days after receipt of the payment from the Granting Authority. The final payment will be received after the end of project Month 36. This payment schedule is intended to guarantee the correct execution of the Project by all Beneficiaries. Funds received by the Coordinator from the Granting Authority and payable to the Beneficiaries SAS and DGSP CSCM, will be paid by the Coordinator solely to the corresponding Affiliated Entities Fundación Para La Gestión De La Investigación en Salud de Sevilla FISEVI (Affiliated Entity linked to Servicio Andaluz de Salud SAS) and FIIBAP (Affiliated Entity linked to Dirección General de Salud Pública de la Consejería de Sanidad de la Comunidad de Madrid DGSP CSCM). Funds received by the Coordinator from the Granting Authority and payable to the Beneficiary ASPB will be used to cover 100% of the cost of the affiliated Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau IRHSCSP (Affiliated Entity linked to Agència Salut Publica de Barcelona ASPB). The Coordinator is entitled to withhold any payments due to a Beneficiary identified by the General Assembly to be in breach of its obligations under this Consortium Agreement or the Grant Agreement or to a Beneficiary which has not yet signed this Consortium Agreement. The Coordinator shall not act in contravention of a decision of the General Assembly, it shall inform the General Assembly of any withholds of payments of a Defaulting Party and it shall abide by any subsequent instructions or decisions -if any- which the General Assembly may take regarding such Defaulting Party. The Coordinator is entitled to recover any payments already paid to a Beneficiary declared as a Defaulting Party except the costs already claimed by the Defaulting Party and accepted by the Granting Authority. The Coordinator is equally entitled to withhold payments to a Beneficiary when this is decided so by the General Assembly based on a suggestion by or action of the Granting Authority. 8 Results 8.1 Ownership of Results Results and the Intellectual Property Rights are owned by (i) the parties that generates them. (ii) or on whose behalf such Result have been generated during the implementation of the Joint Action A contributing Party shall be acknowledged as a co-owner of a Result, irrespective of the nature of its contribution, which may include the provision of relevant resources for the generation of the Result, such as know-how, knowledge, samples, special equipment, information, data sets, and other pertinent assets. Consequently, the Party making such contributions shall be granted a fair share of co-ownership and receive appropriate consideration for their valuable input. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 30 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 8.2 Joint ownership Joint ownership is governed by Grant Agreement Article 16.2 and its Annex 5, Section Ownership of results with the following additions: Joint ownership means two or more Consortium Members shall own Results jointly if: a) they have jointly generated them; and b) it is not possible to establish the respective contribution of each Consortium Member; or separate them for the purpose of applying for, obtaining or maintaining their protection. In case of joint ownership, the joint owners shall make their best efforts to establish a joint-ownership agreement regarding the allocation and terms of exercising such joint ownership as soon as possible and within a maximum of six (6) months as from the date on which the respective Results have been generated and prior to exploitation. Unless otherwise agreed:  each of the joint owners shall be entitled to use their jointly owned Results for non-commercial research and teaching activities on a royalty-free basis, and without requiring the prior consent of the other joint owner(s).  each of the joint owners shall be entitled to otherwise Exploit the jointly owned Results and to grant non-exclusive licenses to Third Parties (without any right to sub-license), if the other joint owners are given: (a) at least 45 calendar days advance notice; and (b) fair and reasonable compensation. The joint owners will engage in good faith discussions to agree on appropriate protection for the results, including a decision on which Party should be responsible for the preparation, filing, and processing of the application(s) and in which countries worldwide they should be filed. Any Party may waive protection in specific countries or territories. If the decision is delayed, a Party may file the first application. Any intellectual property (including patents, patent applications, know-how, trade secrets, copyrights, trademarks) owned by either Consortium Member prior to the date of this Agreement or which – with reference to the relevant Task – were acquired or generated prior to the start of the Joint Action or outside the scope of the Joint Action, shall remain solely owned by such Consortium Member. Each of the Consortium Members shall not during the Joint Action, or at any time thereafter, represent or assert that it is the owner of any such Intellectual Property Rights of the other Consortium Member, whether or not such rights are registered. For the avoidance of doubt, the Consortium Members agree that each of the Consortium Members shall have no rights to use any Intellectual Property Rights of the other, directly or indirectly, for any purpose, except such Consortium Member has granted permission in writing. 8.3 Transfer of Results 8.3.1 Transferring ownership Each Party may transfer ownership of its own Results, including its share in jointly owned Results, following the procedures of the Grant Agreement Annex 5 Each Party may identify specific Third Parties it intends to transfer the ownership of its Results to in Attachment (3) of this Consortium Agreement. The other Parties hereby waive their right to prior notice and their right to object to such a transfer to listed Third Parties according to the Grant Agreement Annex 5. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 31 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 8.3.2 Informing of the transfer The transferring Party shall, however, at the time of the transfer, inform the other Parties of such transfer and shall ensure that the rights of the other Parties under the Consortium Agreement and the Grant Agreement will not be affected by such transfer. Any addition to Attachment (3) after signature of this Consortium Agreement requires a decision of the General Assembly. 8.3.3 Specific cases of mergers and acquisitions The Parties recognise that in the framework of a merger or an acquisition of an important part of its assets, it may be impossible under applicable EU and national laws on mergers and acquisitions for a Party to give at least 45 calendar days prior notice for the transfer as foreseen in the Grant Agreement. 8.3.4 Application of the obligations The obligations above apply only for as long as other Parties still have - or still may request - Access Rights to the Results. 8.4 Dissemination For the avoidance of doubt, the confidentiality obligations set out in Section 10 apply to all dissemination activities described in this Section 8.4 as far as Confidential Information is involved. 8.4.1 Dissemination of own (including jointly owned) Results 8.4.1.1 Dissemination During the Project and for a period of 1 year after the end of the Project, the dissemination of own Results by one or several Parties including but not restricted to publications and presentations, shall be governed by the procedure of Article 17.4 of the Grant Agreement and its Annex 5, Section Dissemination, subject to the following provisions. Prior notice of any planned publication shall be given to the other Parties at least 21 calendar days before the publication. Any objection to the planned publication shall be made in accordance with the Grant Agreement by written notice to the Coordinator and to the Party or Parties proposing the dissemination within 15 calendar days after receipt of the notice. If no objection is made within the time limit stated above, the publication is permitted. 8.4.1.2 Objections to disseminations An objection is justified if a) the protection of the objecting Party's Results or Background would be adversely affected, or b) the objecting Party's legitimate interests in relation to its Results or Background would be significantly harmed, or c) the proposed publication includes Confidential Information of the objecting Party. The objection has to include a precise request for necessary modifications. If an objection has been raised the involved Parties shall discuss how to overcome the justified grounds for the objection on a timely basis (for example by amendment to the planned publication and/or by © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 32 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 protecting information before publication) and the objecting Party shall not unreasonably continue the opposition if appropriate measures are taken following the discussion. The objecting Party can request a publication delay of not more than 45 calendar days from the time it raises such an objection. After 45 calendar days the publication is permitted, provided that the objections of the objecting Party have been addressed. 8.4.1.3 Acknowledgement of EU support Unless otherwise agreed with the Granting Authority, communication activities of the Parties, including their Affiliated Entities, related to the action (including media relations, conferences, seminars, information material, such as brochures, leaflets, posters, presentations, etc., in electronic form, via traditional or social media, etc.), dissemination activities and any infrastructure, equipment, vehicles, supplies or major result funded by the Granting Authority must acknowledge EU support and display the European flag (emblem) and funding statement. The emblem must remain distinct and separate and cannot be modified by adding other visual marks, brands or text. Any communication or dissemination activity related to the action must use factually accurate information. Moreover, it must indicate the following disclaimer (translated into local languages where appropriate): “Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or [name of the granting authority]. Neither the European Union nor the granting authority can be held responsible for them.” 8.4.2 Dissemination of another Party’s unpublished Results or Background A Party shall not include in any dissemination activity another Party's Results or Background without obtaining the owning Party's prior written approval, unless they are already published. Parties shall ensure that this obligation is extended to their Affiliated Entities. 8.4.3 Cooperation obligations The Parties undertake to cooperate to allow the timely submission, examination, publication and defence of any dissertation or thesis for a degree that includes their Results or Background subject to the confidentiality and publication provisions agreed in this Consortium Agreement. 8.4.4 Use of names, logos or trademarks Nothing in this Consortium Agreement shall be construed as conferring rights to use in advertising, publicity or otherwise the name of the Parties or any of their logos or trademarks without their prior written approval. Notwithstanding the foregoing, all such publications or exhibits based on work supported by the Granting Authority must acknowledge the Granting Authority’s support and must mention the grant number and DOI. 9 Access Rights 9.1 Background included 9.1.1 Background included In Attachment 1, the Parties have identified and agreed on the Background for the Project and have also, where relevant, informed each other that Access to specific Background is subject to legal restrictions or limits. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 33 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Anything not identified in Attachment 1 shall not be the object of Access Right obligations regarding Background. 9.1.2 Adding or modifying Background Any Party may add additional Background to Attachment 1 during the Project provided they give written notice to the other Parties. However, approval of the General Assembly is needed should a Party wish to modify or withdraw its Background in Attachment 1. 9.2 General Principles 9.2.1 Implementation of the tasks Each Party, including its Affiliated Entities, shall implement its tasks in accordance with the Consortium Plan and shall bear sole responsibility for ensuring that its acts within the Project do not knowingly infringe Third Party property rights. 9.2.2 Sublicences Any Access Rights granted exclude any rights to sublicense unless expressly stated otherwise. 9.2.3 Administrative transfer costs Access Rights shall be free of any administrative transfer costs. 9.2.4 Granting Access Rights Access Rights are granted on a non-exclusive basis. 9.2.5 Use of Results and Background Results and Background shall be used only for the purposes for which Access Rights to it have been granted. 9.2.6 Request for Access Rights All requests for Access Rights shall be made in writing. The granting of Access Rights may be made conditional on the acceptance of specific conditions aimed at ensuring that these rights will be used only for the intended purpose and that appropriate confidentiality obligations are in place. The requesting Party must show that the Access Rights are Needed. 9.2.7 Extending obligations to Third Parties The Parties shall ensure in their contracts with Third Parties that the obligations of the present section are extended to such entities. 9.3 Access Rights for implementation The Beneficiaries must give each other and the other participants access to the background identified as needed for implementing the action, subject to any specific rules in Annex 5. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 34 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Access Rights to Results and Background Needed for the performance of the own work of a Consortium Member under the Project shall be subject to third party rights, if any, and granted on a royalty-free basis, unless otherwise agreed for Background in Attachment 1. Access Rights to Background if Needed for Exploitation of a Party’s own Results, shall be subject to third party rights, if any, granted on Fair and Reasonable conditions and upon written bilateral agreement between the Party that owns the Background and the Party who requests the access. 9.4 Access Rights for Exploitation 9.4.1 Access Rights to Results Access Rights to Results if Needed for Exploitation of a Party's own Results shall be granted on Fair and Reasonable conditions. Access rights to Results for internal research and for teaching activities shall be granted on a royalty- free basis. 9.4.2 Access Rights to Background Access Rights to Background if Needed for Exploitation of a Party’s own Results, shall be granted on Fair and Reasonable conditions. 9.4.3 Request for Access Eights A request for Access Rights may be made up to twelve months after the end of the Project or, in the case of Section 9.7.2.1.2, after the termination of the requesting Party’s participation in the Project. 9.5 Access Rights for entities under the same control Entities under the same control have Access Rights under the conditions of the Grant Agreement Annex 5, if they are identified in [Attachment 4 (Identified entities under the same control) to this Consortium Agreement]. Such Access Rights must be requested by the entity under the same control from the Party that holds the Background or Results. Alternatively, the Party granting the Access Rights may individually agree with the Party requesting the Access Rights to have the Access Rights include the right to sublicense to the latter's entity under the same control [listed in Attachment 4]. Access Rights to an entity under the same control shall be granted on Fair and Reasonable conditions and upon written bilateral agreement. Entities under the same control which obtain Access Rights in return fulfil all confidentiality obligations accepted by the Parties under the Grant Agreement or this Consortium Agreement as if such entities were Parties. Access Rights may be refused to entities under the same control if such granting is contrary to the legitimate interests of the Party which owns the Background or the Results. Access Rights granted to any entity under the same control are subject to the continuation of the Access Rights of the Party with whom it is under the same control, and shall automatically terminate upon termination of the Access Rights granted to such Party. Upon cessation of the status as an entity under the same control, any Access Rights granted to such former entity under the same control shall lapse. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 35 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Further arrangements with entities under the same control may be negotiated in separate agreements. 9.6 Additional Access Rights For the avoidance of doubt any grant of Access Rights not covered by the Grant Agreement or this Consortium Agreement shall be at the absolute discretion of the owning Party and subject to such terms and conditions as may be agreed between the owning and receiving Parties. The Parties agree to negotiate in good faith any additional Access Rights to Results as might be asked for by any Party, upon adequate financial conditions to be agreed and subject to written bilateral agreement between the Party that owns the Results and the Party who requests the access. 9.7 Access Rights for Parties entering or leaving the consortium 9.7.1 New Parties entering the consortium As regards Results developed before the accession of the new Party, the new Party will be granted Access Rights on the conditions applying for Access Rights to Background. 9.7.2 Parties leaving the consortium 9.7.2.1 Access Rights granted to a leaving Party 9.7.2.1.1 Defaulting Party Access Rights granted to a Defaulting Party and such Party's right to request Access Rights shall cease immediately upon receipt by the Defaulting Party of the formal notice of the decision of the General Assembly to terminate its participation in the consortium. 9.7.2.1.2 Non-defaulting Party A non-defaulting Party leaving voluntarily provided that it gives a thirty (30) days prior notice to the other remaining Parties and with the other Parties' consent shall have Access Rights to the Results developed until the date of the termination of its participation. It may request Access Rights within the period of time specified in Section 9.4.3. 9.7.2.2 Access Rights to be granted by any leaving Party To the extent allowed by law any Party leaving the Project shall continue to grant Access Rights pursuant to the Grant Agreement and this Consortium Agreement as if it had remained a Party for the whole duration of the Project. Termination shall not affect any rights or obligations of a Party leaving the Project incurred prior to the date of termination, unless otherwise agreed between the ultimate decision body in the Consortium and the leaving Party. This includes the obligation to provide all necessary input, deliverables and documents for the period of its participation. The provisions relating to Access Rights, Dissemination and Confidentiality, for the time period mentioned therein, as well as for liability, applicable law and settlement of disputes shall survive the expiration or termination of this Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 36 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 9.8 Specific Provisions for Access Rights to Software For the avoidance of doubt, the general provisions for Access Rights provided for in this Section 9 are applicable also to Software. Parties’ Access Rights to Software do not include any right to receive source code or object code ported to a certain hardware platform or any right to receive respective Software documentation in any particular form or detail, but only as available from the Party granting the Access Rights. 10 Non-disclosure of information 10.1 Confidential information All information in whatever form or mode of communication, which is disclosed by a Party (the “Disclosing Party”) to any other Party (the “Recipient”) in connection with the Project during its implementation and which has been explicitly marked as “confidential” or “sensitive” at the time of disclosure, or when disclosed orally has been identified as confidential at the time of disclosure and has been confirmed and designated in writing within 15 calendar days from oral disclosure at the latest as confidential information by the Disclosing Party, is “Confidential Information”. 10.2 Confidentiality obligations The Recipient hereby undertakes in addition and without prejudice to any commitment on non-disclosure under the Grant Agreement, for a period of 5 years after the final payment of the Granting Authority:  not to use Confidential Information otherwise than for the purpose for which it was disclosed;  not to disclose Confidential Information without the prior written consent by the Disclosing Party;  to ensure that internal distribution of Confidential Information by a Recipient shall take place on a strict need-to-know basis; and  to return to the Disclosing Party, or destroy, on request all Confidential Information that has been disclosed to the Recipient including all copies thereof and to delete all information stored in a machine-readable form to the extent practically possible. The Recipient may keep a copy to the extent it is required to keep, archive or store such Confidential Information because of compliance with applicable laws and regulations or for the proof of on-going obligations provided that the Recipient complies with the confidentiality obligations herein contained with respect to such copy. The Recipient shall be responsible for the fulfilment of the above obligations on the part of its employees or Third Parties involved in the Project and shall ensure that they remain so obliged, as far as legally possible, during and after the end of the Project and/or after the termination of the contractual relationship with the employee or Third Party. 10.3 Exceptions The above shall not apply for disclosure or use of Confidential Information, if and in so far as the Recipient can show that:  the Confidential Information has become or becomes publicly available by means other than a breach of the Recipient’s confidentiality obligations;  the Disclosing Party subsequently informs the Recipient that the Confidential Information is no longer confidential; © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 37 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025  the Confidential Information is communicated to the Recipient without any obligation of confidentiality by a Third Party who is to the best knowledge of the Recipient in lawful possession thereof and under no obligation of confidentiality to the Disclosing Party;  the disclosure or communication of the Confidential Information is foreseen by provisions of the Grant Agreement;  the Confidential Information, at any time, was developed by the Recipient completely independently of any such disclosure by the Disclosing Party;  the Confidential Information was already known to the Recipient prior to disclosure, or  the Recipient is required to disclose the Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order, subject to the provision Section 10.6 hereunder. 10.4 Reasonable care The Recipient shall apply the same degree of care with regard to the Confidential Information disclosed within the scope of the Project as with its own confidential and/or proprietary information, but in no case less than reasonable care. 10.5 Unauthorised disclosure Each Recipient shall promptly inform the relevant Disclosing Party by written notice of any unauthorised disclosure, misappropriation or misuse of Confidential Information after it becomes aware of such unauthorised disclosure, misappropriation or misuse. 10.6 Notifications If any Recipient becomes aware that it will be required, or is likely to be required, to disclose Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order, or – in the case of an Associated Partner – with a reporting requirement from its national funding authority, it shall, to the extent it is lawfully able to do so, prior to any such disclosure.  notify the Disclosing Party, and  comply with the Disclosing Party’s reasonable instructions to protect the confidentiality of the information. 11 Miscellaneous 11.1 Attachments, inconsistencies and severability This Consortium Agreement consists of this core text and:  Attachment 1 (Background included)  Attachment 2 (Accession document)  Attachment 3 (List of Third Parties for simplified transfer according to Section 8.3.2)  Attachment 4 (Identified entities under the same control)  Attachment 5 (NDA for Advisory Board agreed under Section 6) In case the terms of this Consortium Agreement are in conflict with the terms of the Grant Agreement, the terms of the latter shall prevail. In case of conflicts between the attachments and the core text of this Consortium Agreement, the latter shall prevail. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 38 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Should any provision of this Consortium Agreement become invalid, illegal or unenforceable, it shall not affect the validity of the remaining provisions of this Consortium Agreement. In such a case, the Parties concerned shall be entitled to request that a valid and practicable provision be negotiated that fulfils the purpose of the original provision. 11.2 No representation, partnership or agency Except as otherwise provided in Section 6.4.4, no Party shall be entitled to act or to make legally binding declarations on behalf of any other Party or of the consortium. Nothing in this Consortium Agreement shall be deemed to constitute a joint venture, agency, partnership, interest grouping or any other kind of formal business grouping or entity between the Parties. 11.3 Formal and written notices Any notice to be given under this Consortium Agreement shall be addressed to the recipients as listed in the most current address list kept by the Coordinator. Any change of persons or contact details shall be immediately communicated to the Coordinator by written notice. The address list shall be accessible to all Parties. Formal notices: If it is required in this Consortium Agreement (Sections 4.2, 9.7.2.1.1, and 11.4) that a formal notice, consent or approval shall be given, such notice shall be signed by an authorised representative of a Party and shall either be served personally or sent by mail with recorded delivery with acknowledgement of receipt. Written notice: Where written notice is required by this Consortium Agreement, this is fulfilled also by other means of communication such as e-mail with acknowledgement of receipt. 11.4 Assignment and amendments Except as set out in Section 8.3, no rights or obligations of the Parties arising from this Consortium Agreement may be assigned or transferred, in whole or in part, to any Third Party without the other Parties’ prior formal approval. Amendments and modifications to the text of this Consortium Agreement not explicitly listed in Section 6.3. require a separate written agreement to be signed between all Parties. 11.5 Mandatory national law Nothing in this Consortium Agreement shall be deemed to require a Party to breach any mandatory statutory law under which the Party is operating. 11.6 Language This Consortium Agreement is drawn up in English, which language shall govern all documents, notices, meetings, arbitral proceedings and processes relative thereto. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 39 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 11.7 Applicable law This Consortium Agreement shall be construed in accordance with and governed by the laws of Belgium excluding its conflict of law provisions. 11.8 Settlement of disputes The Parties shall endeavour to settle their disputes amicably between themselves before seeking any other kind of resolution or available remedy under applicable law. All disputes arising out of or in connection with this Consortium Agreement, which cannot be solved amicably, shall first be submitted by the Consortium Members to the Work Package Leader concerned. And shall be finally settled by the courts of Brussels. The Coordinator may be involved in the conflict resolution if requested by the Work Package Leader. In case the Work Package Leader fails to reach an amicable agreement within 15 days from the date on which the Dispute was referred to them, the Dispute shall be submitted to the Coordinator which shall aim to recommend a solution by consensus within fifteen (15) days from the date of referral. If consensus cannot be reached, the Dispute shall be submitted to the General Assembly which shall recommend a solution within 30 days. The recommendation shall be taken by simple majority vote, having each General Assembly Member one vote. The parties involved in the dispute shall refrain from participating in such final recommendation. If no agreement is reached, the Coordinator, after consultation with the Project Officer of the Granting Authority, shall make a final recommendation on the issue. If the Coordinator is involved in the conflict, another Consortium Member selected jointly by the General Assembly should take over this role. Should the above mechanisms fail to find a solution to the satisfaction of the concerned Consortium Members, the dispute shall be subject to the jurisdiction of the competent Court of Brussels. Nothing in this Consortium Agreement shall limit the Consortium Members' right to seek injunctive relief in any applicable competent court. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 40 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 12 Signatures AS WITNESS: The Parties have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. The Parties agree that advanced and qualified electronic signatures, within the meaning of the European regulation "Electronic identification and trust services", known as the "eIDAS Regulation" of 1 July 2016, shall have the same legal value and probative force as original signatures, and that in the event of any dispute or claim arising out of the Consortium Agreement, each of the Parties hereby waives the right to invoke any defence and/or waiver based on the signature of the Consortium Agreement by means of a scanned or digitized image of a handwritten signature (e.g. scan in PDF format) and/or an electronic signature. ASOCIACIÓN INSTITUTO DE INVESTIGACIÓN EN SISTEMAS DE SALUD BIOSISTEMAK (BIOSISTEMAK) Signature Name: Ane Fullaondo Zabala Title: Scientific Director Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 41 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Agencia de Salut Publica de Barcelona (ASPB) Signature Name: Dr. Carme Borrell Title: Director Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 42 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 CONSEJERIA DE SANIDAD DE LA COMUNIDAD DE MADRID (DGSP CSCM) Signature Name: Elena Andradas Aragonés Title: Directora General de Salud Pública Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 43 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (IDIBAPS), Signature Name: Mr. David Badia i Prat Title: Managing Director Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 44 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA (IDIVAL), Signature Name: Francisco Galo Peralta Title: Managing Director Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 45 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 FUNDACION PUBLICA MIGUEL SERVET (FMS) Signature Name: Javier Gómez-Arrue Azpiazu Title: Director Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 46 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 SERVICIO ANDALUZ DE LA SALUD (SAS) Signature Name: Inmaculada Vázquez Title: Managing Director – SAS – Hospital Virgen de Valme Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 47 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 GESUNDHEIT ÖSTERREICH GMBH (GÖG) Signature Name: Ms. Claudia Habl Title: Chief Operating Officer (COO) / Legal Entity Appointed Representative (LEAR) Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 48 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 SCIENSANO (Sciensano) Signature Name: Christian Léonard Title: Managing director Date: © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 49 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH) Signature Name: Assoc. Prof. Krunoslav Capak, MD, PhD Title: Director-General Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 50 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 ORGANISMOS KRATIKON YPIRESION YGEIAS (SHSO) Signature Name: Irene Procopiou Title: Chief Operating Officer Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 51 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 NARODNI USTAV DUSEVNIHO ZDRAVI (NIMH) Signature Name: Ph. Dr. Petr Winkler, Ph.D. Title: Director Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 52 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 REGION SJAELLAND (RZDK) Signature Name: Søren Stig Tvilsted Title: Legal signatory for JA-PRISM Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 53 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 SOTSIAALMINISTEERIUM (MSAE) Signature Name: Maarjo Mändmaa Title: Chancellor Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 54 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 TERVEYDEN JA HYVINVOINNIN LAITOS (THL) Signature Name: Mika Salminen Title: Director General Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 55 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 MINISTERE DU TRAVAIL, DE LA SANTE, DES SOIDARITES ET DES FAMILLES (MoH FR), Signature Name: M. Emilien ROGER Title(s): Sous-directeur de l'appui au pilotage et ressources, Direction générale de la santé Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 56 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 BUNDESINSTITUT FÜR ÖFFENTLICHE GESUNDHEIT (BIÖG) Signature Name: Dr. Johannes Nießen Title: Acting Director Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 57 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 ETHNIKOS ORGANISMOS DIMOSIAS YGEIAS (EDOY) Signature Name: Christakis Chatzichristodoulou Title: President of the Board Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 58 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 ORSZAGOS KORHAZI FOIGAZGATOSAG (OKFO) Signature Name: Dr. Révész János Title: Főigazgató (Director General) Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 59 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 ISTITUTO SUPERIORE DI SANITA (ISS) Signature Name: Rocco Domenico Alfonso Bellantone Title: President Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 60 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 BERNU KLINISKA UNIVERSITATES SLIMNICA VALSTS SIA (BKUS) Signatures Name: Valts Ābols Title: CEO Date Name: Zane Straume Title(s): Board member Date Name: Marija Hramcova Title: Board member Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 61 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (SAM) Signature Name: Austėja Tamaliūnaitė Title: Mental Health Unit Counsellor Date : © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 62 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 VILNIAUS UNIVERSITETAS (VU) Signature Name: prof. Rimvydas Petrauskas Title: Rector Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 63 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 LIETUVOS SVEIKATOS MOKSLU UNIVERSITETAS (LSMU) Signature Name: Prof. Rimantas Benetis Title: Rector Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 64 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 MINISTARSTVO ZDRAVLJA (MoH MNE) Signature Name: dr Vojislav Šimun Title: Minister Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 65 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 MINISTERIO DA SAUDE (MS) Signature Name: Ana Pedroso Title: Secretary-General of the Ministry of Health Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 66 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ) Signature Name: Branko Gabrovec Title: PhD, Assoc.Prof., General Director Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 67 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PUBLIC HEALTH INSTITUTE OF THE REPUBLIC OF SRPSKA (PHI RS) Signature Name: Bojan Đenić Title: Bachelor of Law Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 68 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 THE FEDERAL MINISTRY OF HEALTH (FMOH) Signature Name: NEDILJKO RIMAC Title: Minister Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 69 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 JAVNA ZDRAVSTVENA USTANOVA DOM ZDRAVLJA BANJA LUKA (DZ BL) Signature Name: Nevena Todorovic Title: M.D.,Ph.D.,Asst. Prof. Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 70 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 ASSOCIATED PARTNER: SERVICIO MADRILEÑO DE SALUD (SERMAS) Signature Name: Title: Date © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 71 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Attachment 1: Background included According to the Grant Agreement (Article 16.1) Background is defined as “data, know-how or information (…) that is (…) needed to implement the Action or exploit the results”. Because of this need, Access Rights have to be granted in principle, but Parties must identify and agree amongst them on the Background for the Project. This is the purpose of this attachment. PARTY 1 As to BIOSISTEMAK, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of BIOSISTEMAK is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 72 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 2 As to ASPB, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of ASPB is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 73 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 3 As to DGSP CSCM, it is agreed between the Parties that, to the best of their knowledge, Data, Know How, development and virtualization of content for publication through the virtual platform of the Civil Service of the Community of Madrid, the intellectual knowledge and/or software-platform developed or made available within the framework of this project will have no inherent restrictions on use. However, the terms of use will be requested and provided in detail prior to any application or dissemination, ensuring transparent and coordinated management of resources. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 74 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 4 As to IDIBAPS, it is agreed between the Parties that, to the best of their knowledge, the following Background is hereby identified and agreed upon for the Project. Specific limitations and/or conditions, shall be as mentioned hereunder: Describe Background Specific restrictions and/or Specific restrictions and/or conditions for implementation conditions for Exploitation (Article 16.4 Grant Agreement (Article 16.4 Grant and its Annex 5, Section Agreement and its Annex 5, “Access rights to results and Section “Access rights to background”, sub-section results and background”, “Access rights to background sub-section “Access rights and results for implementing for exploiting the results”) the Action”) Data, know-how, tools, The Access Rights will be granted In case a Party/ies wishes to intellectual property rights, to the extent that it is needed for use this Background for techniques, material, results, implementation of the action and another project, for beyond the expertise and methods from to the extent that said Background duration of the Project or for the research group/s of FRCB- is not subject to terms and commercial, non-research or IDIBAPS /HCB directly conditions in other agreements educational purposes, its use involved in carrying out the that may prohibit the desired will be subject to specific Project and which are Access Right. The Background agreements between FRCB- necessary for the development will be made available for the IDIBAPS /HCB and the of the Project. duration of the Project itself. Party/ies under fair and Access to certain Background reasonable market condition and/or Material may be subject to special conditions (Material Transfer Agreements, Data Transfer Agreements, terms of use, etc.). © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 75 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 5 As to IDIVAL, it is agreed between the Parties that, to the best of their knowledge, the following Background is hereby identified and agreed upon for the Project. Specific limitations and/or conditions, shall be as mentioned hereunder: Describe Background Specific restrictions and/or Specific restrictions and/or conditions for implementation conditions for Exploitation (Article 16.4 Grant Agreement (Article 16.4 Grant and its Annex 5, Section Agreement and its Annex 5, “Access rights to results and Section “Access rights to background”, sub-section results and background”, “Access rights to background sub-section “Access rights and results for implementing for exploiting the results”) the Action”) DATA SETS with clinical data, The use of the background is Non authorized. EVALUATION AND subject to restrictions arising from ANALYSIS SYSTEM the scope of the transfer of PROTOCOLS: These personal data that patients have protocols include the Datasets made to IDIVAL.Background can collection procedures, the only be used for the design and implementation implementation of the Project if phases and procedures Needed, for research purposes description. and complying with the confidentiality requirements provided for in this agreement for information or data qualified as Confidential Information. Once the background has been used for the intended purpose it shall be destroyed. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 76 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 6 As to FMS, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of FMS is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 77 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 7 As to SAS, it is agreed between the Parties that, to the best of their knowledge, the Background to which the Andalusian Health Service is ready to grant access rights, when needed for the performance of the Project, is limited to that provided by the PI Matilde Blanco Venzalá or members of her research team. For the avoidance of doubt, the Andalusian Health Service excludes from access rights specifically: - any Background which has been developed by any SAS employee other than the PI or members of her research team directly involved in the Project; - any data, result, know-how, invention, patentable or not, technology, intellectual property right, report, method or any other kind of information which is property of SAS and/or has been generated by the PI is not needed for the performance of the Project; - and any background subject to Third Party’s rights, non-disclosure agreements or any other legal provisions preventing the granting of Access Rights. This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 78 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 8 As to GÖG, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of GÖG is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 79 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 9 As to Sciensano, it is agreed between the Parties that, to the best of their knowledge, no data, know- how or information of Sciensano is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 80 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 10 As to CIPH, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of CIPH is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 81 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 11 As to SHSO, it is agreed between the Parties that, to the best of their knowledge, No data, know-how or information of SHSO is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 82 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 12 As to NIMH, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of NIMH is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 83 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 13 As to RZDK, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of RZDK is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 84 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 14 As to MSAE, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of MSAE is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 85 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 15 As to THL, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of THL is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 86 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 16 As to MoH FR, it is agreed between the Parties that, to the best of their knowledge, the following Background is hereby identified and agreed upon for the Project. Specific limitations and/or conditions, shall be as mentioned hereunder: Describe Background Specific restrictions and/or Specific restrictions and/or conditions for implementation conditions for Exploitation (Article 16.4 Grant Agreement (Article 16.4 Grant and its Annex 5, Section Agreement and its Annex 5, “Access rights to results and Section “Access rights to background”, sub-section results and background”, “Access rights to background sub-section “Access rights and results for implementing for exploiting the results”) the Action”) INSERM: Development of INSERM: Implementation limited INSERM:No exploitation communication tools and under supervision and control of possible resources for early detection Inserm and intervention INSERM Development of a INSERM: The tool is protected pre-screening tool for facilitating orientation PRIMO © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 87 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 17 As to BIÖG, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of BIÖG is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 88 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 18 As to EODY, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of EODY is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 89 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 19 As to OKFO, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of OKFO is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 90 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 20 As to ISS, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of ISS is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 91 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 21 As to BKUS, it is agreed between the Parties that, to the best of their knowledge,: No data, know-how or information of BKUS is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 92 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 22 As to SAM, it is agreed between the Parties that, to the best of their knowledge, the following Background is hereby identified and agreed upon for the Project. Specific limitations and/or conditions, shall be as mentioned hereunder: Describe Background Specific restrictions and/or Specific restrictions and/or conditions for implementation conditions for Exploitation (Article 16.4 Grant Agreement (Article 16.4 Grant and its Annex 5, Section Agreement and its Annex 5, “Access rights to results and Section “Access rights to background”, sub-section results and background”, “Access rights to background sub-section “Access rights and results for implementing for exploiting the results”) the Action”) Methodological resources and Implementation limited under the No exploitation reseources for early detection supervision and control of SAM. and intervention. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 93 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 23 As to VU, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of Vilnius University is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 94 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 24 As to LSMU, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of LSMU is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 95 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 25 As to MoH MNE, it is agreed between the Parties that, to the best of their knowledge, no data, know- how or information of MoH MNE is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 96 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 26 As to MS, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of MS is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 97 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 27 As to NIJZ, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of NIJZ is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 98 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 28 As to PHI RS, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of PHI RS is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 99 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 29 As to FMoH, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of FMoH is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 100 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 PARTY 30 As to DZ BL, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of DZ BL is Needed by another Party for implementation of the Project (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub-section “Access rights to background and results for implementing the action”) or Exploitation of that other Party’s Results (Article 16.1 and its Annex 5 Grant Agreement, Section “Access rights to results and background”, sub- section “Access rights for exploiting the results”). This represents the status at the time of signature of this Consortium Agreement. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 101 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Attachment 2: Accession document ACCESSION of a new Party to [Acronym of the Project] Consortium Agreement, version […, YYYY-MM-DD] [OFFICIAL NAME OF THE NEW PARTY AS IDENTIFIED IN THE Grant Agreement] hereby consents to become a Party to the Consortium Agreement identified above and accepts all the rights and obligations of a Party starting [date]. [OFFICIAL NAME OF THE COORDINATOR AS IDENTIFIED IN THE Grant Agreement] hereby certifies that the consortium has accepted in the meeting held on [date] the accession of [the name of the new Party] to the consortium starting [date]. This Accession document has been done in 2 originals to be duly signed by the undersigned authorised representatives. [Date and Place] [INSERT NAME OF THE NEW PARTY] Signature(s) Name(s) Title(s) [Date and Place] [INSERT NAME OF THE COORDINATOR] Signature(s) Name(s) Title(s) © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 102 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Attachment 3: List of Third Parties for simplified transfer according to Section 8.3.2. The following Third Parties which are linked to a Beneficiary will participate in PRISM as Affiliated Entities’:  For Agencia de Salut Publica de Barcelona: (IR SANT PAU) INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU FUNDACIÓ, PIC 998869432,  For DGSP: CSCM CONSEJERIA DE SANIDAD DE LA COMUNIDAD DE MADRID: (FIIBAP) FUNDACION PARA LA INVESTIGACION E INNOVACION BIOSANITARIA DE ATENCION PRIMARIA, PIC 919231753,  For IDIBAPS: FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER: (HCB): HOSPITAL CLINIC DE BARCELONA, PIC 905096816,  For SAS: SERVICIO ANDALUZ DE LA SALUD: (FISEVI) FUNDACION PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA, PIC 994159888,  For SCIENSANO: (FPSPublicHealth) SERVICE PUBLIC FEDERAL SANTE PUBLIQUE, SECURITE DE LA CHAINE ALIMENTAIRE ET ENVIRONNEMENT, PIC 998853815,  For SHSO: ORGANISMOS KRATIKON YPIRESION YGEIAS, (UCY) UNIVERSITY OF CYPRUS, PIC 999835843,  For RZDK: REGION SJAELLAND: o (Odsherred Kom) ODSHERRED KOMMUNE, PIC 877136760, o (BORNHOLMKOM) BORNHOLMS REGIONSKOMMUNE, PIC 907528509, o (VEJLE KOMMUNE) VEJLE KOMMUNE, PIC 937383072,  For MoH-FR: MINISTRE DU TRAVAIL, DE LA SANTE, DE LA SOIDARITE ET DES FAMILLES: o ORSPERE-SAMDARRA (CH Le Vinatier), PIC 948558636, o (INSERM) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, PIC 999997833,  For EODY: ETHNIKOS ORGANISMOS DIMOSIAS YGEIAS: o (UMHRI) UNIVERSITY MENTAL HEALTH, NEUROSCIENCES AND PRECISION MEDICINE RESEARCH INSTITUTE COSTAS STEFANIS, PIC 994633927, o (2 DYPE) 2 YGEIONOMIKI PERIFEREIA PEIRAIOS KAI AIGAIOU, PIC 880690064, o (POKOISPE) PANELLINIA OMOSPONDIA KOINONIKON SYNETAIRISMON PERIORISMENIS EFTHINIS, PIC 874094355,  For (OKFO) ORSZAGOS KORHAZI FOIGAZGATOSAG: o (Bethesda) MAGYARORSZAGI REFORMATUS EGYHAZ BETHESDA GYERMEKKORHAZA, PIC 918286488, o (NNGYK) NEMZETI NEPEGESZSEGUGYI ES GYOGYSZERESZETI KOZPONT, PIC 998706957, o (SJCH) ESZAK-BUDAI SZENT JANOS CENTRUMKORHAZ, PIC 889719212  For (ISS) ISTITUTO SUPERIORE DI SANITA o ( UCSC) UNIVERSITA CATTOLICA DEL SACRO CUORE, PIC 999915771 o (UNIBO) ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA, PIC 999993953  (ATS MILANO) AGENZIA DI TUTELA DELLA SALUTE DELLA CITTA METROPOLITANA MILAN, PIC 877825363, o (AUX) ISTITUTO AUXOLOGICO ITALIANO, PIC 997997208, o (PROMIS) AZIENDA ULSS 4 VENETO ORIENTALE, PIC 953342870  For (BKUS) BERNU KLINISKA UNIVERSITATES SLIMNICA VALSTS SIA: o (NPVC) NACIONALAIS PSIHISKAS VESELIBAS CENTRS, VALSTS SIA, PIC 881163036 © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 103 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 o (CARC) "Bernu un pusaudzu resursu centra atbalsta fonds", PIC 882841427  For (SAM) LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA, o (HI) HIGIENOS INSTITUTAS, PIC 941996780  For (MoH) MNE MINISTARSTVO ZDRAVLJA o (CCoM) KLINICKI CENTAR CRNE GORE PODGORICA, PIC 929443913 o (IPH) MNE ZDRAVSTVENA USTANOVA INSTITUT ZA JAVNO ZDRAVLJE PODGORICA PIC 998754681  For (MS) MINISTERIO DA SAUDE o (UNL) UNIVERSIDADE NOVA DE LISBOA, PIC 960782479 © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 104 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Attachment 4: Identified entities under the same control according to Section 9.5 PART LEFT INTENTIONALLY IN BLANK © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 105 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 Attachment 5: NDA for Advisory Board agreed under Section 6 THIS AGREEMENT [the Agreement] is entered into on this [insert number of day] day of [insert Month and year] by and between: The ASOCIACIÓN INSTITUTO DE INVESTIGACIÓN EN SISTEMAS DE SALUDBIOSISTEMAK, having its registered office at RONDA DE AZKUE 1 TORRE DEL BILBAO EXHIBITION CENTRE, BARAKALDO (Spain), hereinafter referred to as “the Coordinator” or Biosistemak” or “the Disclosing Party”, Acting in the names and on behalf of the PRISM Consortium Members, and [insert name of the Entity or Title and name], established in [insert full address] and represented by [title] [last name and name]/born on [insert date] in [insert place], [insert country], of [insert nationality] nationality, living at [insert postal address], hereinafter referred to as “the Receiving Party” BIOSISTEMAK and the Receiving Party shall hereafter be referred to collectively as the “Parties” and individually as a “Party”. Preamble: Whereas the European Community represented by the European Health and Digital Executive Agency (HADEA) agreed on granting a financial contribution for the implementation of the project called “Joint Action Prevention oriented RIghts-based approach to Support Mental health in vulnerable population groups” (PRISM) (hereinafter referred to as the “Project”) coordinated by BIOSISTEMAK which terms and conditions are established in Grant Agreement n° [101233316]. Whereas the consortium members of the Project (hereinafter “Consortium Members”) possesses certain scientific and/or technical confidential information in the field of the Project. The Consortium Members are not deemed Third Parties for the purposes of this Agreement. Whereas BIOSISTEMAK, as coordinator of the Project, is in charge of entering in a non-disclosure agreement with the Receiving Party in the name and on behalf of the Consortium Members, for the purpose of enabling the Receiving Party to act as an independent expert in the Scientific Advisory Board of the Project and to provide advice to the Project operational bodies (the “Purpose”). Whereas the Receiving Party is active in the field of [insert expertise]. Whereas the Receiving Party, aware that the disclosure of confidential information by Consortium Members could affect their policies in research valorisation and/or marketing, agrees to sign the present non-disclosure Agreement which sets up rules for its use and protection. It is understood that the Confidential Information may include Confidential Information of the Consortium Members and that BIOSISTEMAK is authorized to disclose them. The Receiving Party agrees that Confidential Information can be shared with Consortium Members, and that each Consortium Member shall be entitled to enforce the terms of this Agreement. Whereupon, the parties have agreed as follows: Preliminary Article: Definitions © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 106 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 "Agreement" refers to this agreement, including any amendment and exhibits hereto, which form an integral part hereof. "Confidential Information" All information in whatever form or mode of communication, which is disclosed by the Disclosing Party to the Receiving Party in connection with the Project during its implementation and which has been explicitly marked as “confidential” at the time of disclosure, or when disclosed orally has been identified as confidential at the time of disclosure and has been confirmed and designated in writing within 15 calendar days from oral disclosure at the latest as confidential information by the Disclosing Party, is “Confidential Information”. “Confidential Information” or “Sensitive Information” is the information:  oral or written, communicated by a Consortium Member ("Issuing Party") to the other Consortium Member ("Receiving Party") for the purpose of executing the Joint Action, including, but not limited to: information of a scientific, technical, financial, legal, tax and commercial nature, business models and strategies, ideas, inventions, concepts, business plans, new products, contracts, know-how, logo design, technologies, names of potential clients and partners, projects and operations of any nature proposed or under study, reports, instructions, recommendations, drawings, plans, market projections and data, together with analyses and working documents, compilations, comparisons, studies and, in general, all information that the Parties transmit to each other, whether prior to or after the signing of this Consortium Agreement.  which has been explicitly marked as “confidential” or “sensitive” at the time of disclosure by the Disclosing Party, or when disclosed orally has been identified as "confidential" or "sensitive" at the time of disclosure and has been confirmed and designated in writing within fifteen (15) calendar days from oral disclosure at the latest as "confidential" or "sensitive" information by the Disclosing Party. However, the absence of such identification shall not negate the confidential nature of such information. The Confidential Information relates in particular to the Project. Singular terms can be read in the plural and vice versa. 1. Purpose, nature and scope of this agreement 1.1 The purpose of this Agreement is to define the terms and conditions under which the Receiving Party undertakes to observe the strictest secrecy regarding all Confidential Information disclosed for the Purpose. 1.2 BIOSISTEMAK and/or other Consortium Members may pass on to the Receiving Party, any Confidential Information it/they deem(s) necessary for the Purpose on a non-exclusive basis. 1.3 It is hereby agreed that BIOSISTEMAK and/or the other Consortium Members give no warranty regarding the Confidential Information it passes on to the Receiving Party, in particular as regards its relevance for the Purpose. 1.4 The Parties agree that this Agreement shall under no circumstances create any privity beyond the purpose for which it has been drawn up, and all the more does not imply the conclusion of any other contracts whatsoever. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 107 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 1.5 All Confidential Information disclosed to the Receiving Party, and any and all copies that may have been made thereof, remain the ownership of BIOSISTEMAK and/or the other Consortium Members as the case may be. 2. Scope of the obligation of confidentiality 2.1 The Receiving Party undertakes to observe, maintain and protect the strictest secrecy with regard to the Confidential Information it is given under this Agreement, and shall protect the said Confidential Information as it would protect its own Confidential Information. 2.2 In this respect, the Receiving Party undertakes to take all necessary precautions to deny Third Parties access to the Confidential Information it receives. 2.3 In particular, the Receiving Party undertakes not to disclose the Confidential Information to any Third Party. 2.4 If in spite of all precautions one or more documents or media containing Confidential Information, or the Confidential Information itself, were to disappear or be disclosed, the Receiving Party undertakes to immediately inform BIOSISTEMAK as from their/its disappearance or disclosure. 2.5 The Receiving Party shall remain liable for compliance with the confidential nature of the Confidential Information. 3. Use of the Confidential Information 3.1 The Receiving Party undertakes to use the Confidential Information solely for the Purpose. Any other use of the Confidential Information shall therefore be subject to a specific agreement between the Parties. 3.2 The Confidential Information shall only be used, reproduced or disclosed internally. 3.3 The Receiving Party expressly agree that disclosure of the Confidential Information under this Agreement shall on no account be construed as explicitly or implicitly granting the Receiving Party any right whatsoever (under a licence or any other way), in particular to substances, inventions, creations, results or discoveries this Confidential Information relates to, which may or may not be covered by an intellectual property right. The same applies for author’s rights or any other rights attached to the literary and artistic proprietary (copyright), trademarks or trade secrets. In particular, the Receiving Party undertakes not to file any patent application, directly or indirectly, or any other industrial property rights, which includes or implements all or part of the Confidential Information or which refers to it. 4. Limitations Notwithstanding the foregoing Articles, the Receiving Party is under no obligation and is subject to no restriction regarding any Confidential Information for which it can prove that: a. it was either available to the public or was released in the public domain after it was received by the Receiving Party, through no fault of its own, or b. it was lawfully received from a Third Party without restrictions or any breach of this Agreement, or © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 108 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 c. it was disclosed with the written permission of BIOSISTEMAK and/or the other Consortium Members from which it originated, or d. it was already in the possession of the Receiving Party, or e. it was developed by the Receiving Party independently of the Confidential Information received, or f. it was disclosed by application of a mandatory, statutory or regulatory provision or pursuant to a final and binding court decision. Nevertheless, in the latter cases, the Receiving Party which was constrained to disclose the Confidential Information may be held liable if any of the following conditions are not met: (i) it shall, to the extent it is not prohibited by law, first inform BIOSISTEMAK and/or the other Consortium Members, as the case may be, in writing of its obligation to disclose the Confidential Information in such a way that they have enough time to object or to limit the scope of such disclosure, if need be; (ii) it must confine such disclosure to what is strictly necessary for it to meet its obligations. 5. Entire agreement All the provisions of this Agreement constitute the entire agreement between the Parties with regard to its purpose and supersede any and all prior oral or written statements, negotiations, representation, communications, acceptances, understandings and agreements between the Parties in connection with the Purpose and the provisions to which this Agreement applies or stipulates. It is understood by the Parties that the Receiving Party retains full independence in the execution of the Purpose, hence the present Agreement shall not in any event be deemed or considered as creating hierarchical relationship, nor as constituting an employment contract between the Receiving Party and the Consortium Members. 6. Duration 6.1 This Agreement shall take enter into force [day-month-year], for the duration of the project, i.e. until [day-month-year]. 6.2 Notwithstanding the termination or the expiration of this Agreement for any reason, the Parties remain bound by the confidentiality obligations until the Confidential Information is made available for the public and without any infringement of the Agreement. 7. Term and causes of resolution: This Agreement shall enter into force upon signature, but shall extend to previously disclosed Confidential Information. This Agreement shall remain in effect as long as the Confidential Information has not entered the public domain without the Receiving Party's breach of this Agreement 8. The Recipient, as a member of the Advisory Board, agrees to disclose to the Discloser any actual or potential conflicts of interest, including but not limited to: i. Financial interests in any company or entity that is a competitor of the Discloser or that has business dealings with the Discloser. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 109 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 ii. Any consulting, employment, or advisory relationships with companies or entities that are competitors of the Discloser or that have business dealings with the Discloser. iii. Any personal or familial relationships that could potentially influence the Recipient's judgment or advice. 9. Termination 7.1 This Agreement may be terminated ipso jure by either Party, at any time and for any reason, subject to a thirty (30) days' notice given by registered letter with acknowledgement of receipt, the other Party not being entitled to claim any form of compensation. 7.2 Early termination of this Agreement shall not discharge the Receiving Party from its obligations as regards the use, disclosure and protection of the received Confidential Information, nor shall it alter the scope thereof; these obligations remain in force for the term specified in 6.2. 10. Returning the Confidential Information Upon request, as well following the end of the Agreement, the Receiving Party shall within ten (10) days of receiving such a request: a. at the BIOSISTEMAK’s and/or, as the case may be, the other Consortium Members’ discretion, return or destroy all original copies of documents, equipment, electronic or other medium containing the Confidential Information or their summaries in its possession b. issue a formal written statement certifying that it has not retained any Confidential Information and/or copies of the said Confidential Information on any medium whatsoever, with the exception of a single copy that it may retain in its statutory archives with a view to monitoring its commitments under the Agreement. The Parties acknowledge that any unauthorized disclosure and use of the Confidential Information may cause damages to the Discloser that may be difficult to quantify. Therefore, the Parties agree that the Discloser shall have the right to seek legal action before the competent courts and obtain compensation from the other Party for the damages caused by such unauthorized disclosure and use. 11. Assignment The Agreement is entered into intuitu personae. Consequently, it is personal, non-transferable and nonassignable. 12. Validity If any provisions of this Agreement are invalid or unenforceable, the validity of the remaining provisions shall not be affected. The invalid or unenforceable provision shall be replaced by a valid and enforceable provision that will meet the purpose of the invalid or unenforceable provision as closely as possible. 13. Subsequent Agreements Ancillary agreements, amendments or additions hereto shall be made in writing. 14. Communications © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 110 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 All notifications, requests, demands, and other communications that may or must be made by the Parties in relation to this Agreement must be in writing and will be deemed to have been duly made when sent by any means that proves receipt and content to the address and for the attention of the persons listed in the heading of this Agreement. However, purely administrative communications, lacking interpretative relevance or contractual effects, may be exchanged by fax or email, without an advanced digital signature. Any change of address by one of the Parties must be notified to the other immediately and by a means that guarantees receipt of the message. 15. Conflicts of interest: The Recipient, as a member of the Advisory Board, agrees to disclose to the Discloser any actual or potential conflicts of interest, including but not limited to: i. Financial interests in any company or entity that is a competitor of the Discloser or that has business dealings with the Discloser. ii. Any consulting, employment, or advisory relationships with companies or entities that are competitors of the Discloser or that have business dealings with the Discloser. iii. Any personal or familial relationships that could potentially influence the Recipient's judgment or advice. 16. Miscelanea: 16.1. Neither Party shall undermine and/or avoid this Confidentiality Agreement, whether directly or indirectly, particularly through Affiliates, actions of institutions, sales and distribution organizations, or any other third party. 17. Data protection: The Parties declare their recognition and respect for current legislation regarding the protection of personal data. Thus, as a result of the execution of the Confidentiality Agreement, should one of the Parties access personal data in the files of the other Party, the provisions of Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016, on the protection of natural persons with regard to the processing of personal data and on the free movement of such data shall apply. 18. Governing law, settlement of disputes This Agreement shall be construed and interpreted by the laws of Belgium. The court of the defendant shall have jurisdiction. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 111 / 112  PRISM Consortium Agreement, version 1.1, 11th July 2025 IN WITNESS WHEREOF, the Parties hereto have caused this Non-Disclosure Agreement to be executed as of the date stated above. Signed counterparts of this Agreement delivered by facsimile or by scanned portable document format (.pdf) image shall be deemed to be originals for all purposes. Biosistemak Signature ____________________________ Name: Title: The Receiving Party [insert name] Signature ____________________________ Name: Title: Prof./Dr. © DESCA - Model Consortium Agreement for Horizon Europe, www.desca-agreement.eu Version DESCA HE 2.0, February 2024 112 / 112